Clinical trial register · Portugal

Clinical Trials in Porto, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Portugal and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 1102 matching records held by the registry are in this view. Synced 11 Nov 2026, 03:18 UTC

1102

Studies in scope

all four open statuses

529

Recruiting now

open to new participants

282

Lead sponsors

across recruiting studies

Top sites

Lisbon 691 Porto 539 Coimbra 254 Braga 184 Vila Nova de Gaia 109

Trials with a site in Porto

Status

Study

Lead sponsor

Phase

Enrol

Sites in Portugal

Start

Not yet open

A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

NCT07915219Bronchiectasis

DrugVerducatib

Boehringer Ingelheim

Phase 3

1,500

Aveiro, Braga, Coimbra, Guimarães, Leiria, Lisbon, Porto

2027-01-11

Not yet open

Efficacy of Tirzepatide for Weight Management in Patients With Suboptimal Weight Loss After Bariatric Surgery: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

NCT07829198Obesity

DrugTirzepatide

Universidade do Porto

Phase 3

Porto, Santa Maria da Feira

2027-01

Not yet open

Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

NCT07441408Pulmonary Fibrosis

DrugAdmilparant

Bristol-Myers Squibb

Phase 3

2,380

Vila Nova de Gaia, Lisbon, Loures, Porto

2026-12-16

Not yet open

A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma

NCT07728188Relapsed or Refractory Multiple Myeloma

DrugsEtentamig·Teclistamab·Carfilzomib·Pomalidomide

AbbVie

Phase 3

520

Lisbon, Vila Nova de Gaia, Braga, Porto

2026-11-30

Not yet open

Study of PM54 in Combination With Cytotoxic and Targeted Agents in Adult Participants With Advanced Malignancies

NCT07839819Advanced Solid Tumor

DrugsPM54·Doxorubicin·Irinotecan

PharmaMar

Phase 1/2

231

Lisbon, Porto

2026-11-12

Not yet open

TBLC vs NIVATS in Interstitial Lung Disease

NCT07910448Interstitial Lung Diseases (ILD)

Rita Alexandra Afonso da Costa

Not applicable

Porto

2026-11-02

Not yet open

Proprioceptive Versus Strengthening Exercises for Patellofemoral Pain

NCT06893289Patellofemoral Pain

Universidade do Porto

Not applicable

Porto

2026-10-12

Recruiting

A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma

NCT07768189Oropharyngeal Carcinoma (OPC)

DrugsCRB-701·Cetuximab·Docetaxel

Corbus Pharmaceuticals Inc.

Phase 3

260

Lisbon, Porto

2026-09-29

Recruiting

Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)

NCT07817875Obesity

DrugTirzepatide

Eli Lilly and Company

Phase 3

150

Lisbon, Porto

2026-09-25

Recruiting

A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum

NCT07811193Colorectal Adenocarcinoma

DrugsVVD-133214·Pembrolizumab

Vividion Therapeutics, Inc.

Phase 2

140

Coimbra, Lisbon, Porto

2026-09-11

Recruiting

A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned

NCT07665450Multiple Myeloma

DrugsRamantamig·Bortezomib·Daratumumab·Lenalidomide

Janssen Research & Development, LLC

Phase 3

1,000

Braga, Lisbon, Porto, Vila Real

2026-09-09

Not yet open

Influence of Osteopathic Intervention on Cervical Muscles in Tension Headaches in Women

NCT06475248Tension Headaches

Escola Superior de Tecnologia da Saúde do Porto

Not applicable

Porto

2026-09

Not yet open

Prevention of Psoriatic Arthritis Inflammation Through Digital Care: A Feasibility Mixed-Methods Study

NCT07772544Psoriatic Arthritis (PsA)

Sociedade Portuguesa de Reumatologia

Not applicable

Aveiro, Lisbon, Porto

2026-09

Not yet open

TIVA Mobile Health Intervention for Family Caregivers

NCT07616284Positive Mental Health, Family Caregivers, Mental Health Promotion, Caregiver Burden

Universidade do Porto

Not applicable

Porto

2026-09

Recruiting

A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus

NCT07630714Systemic Lupus Erythematosus

AstraZeneca

Phase 2

Lisbon, Porto

2026-08-31

Recruiting

Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment

NCT07691970Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus

DrugAnifrolumab

AstraZeneca

Phase 3

1,072

Braga, Lisbon, Porto

2026-08-31

Not yet open

MyGENESIS-PATH: Digital Program for Donor-Conceived People

NCT07457697Psychosocial Stress

Universidade do Porto

Not applicable

Porto

2026-08-18

Recruiting

Phase 3 Trial of Reltodecacog Alfa (VMX-C001) vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin.

NCT07288489Blood Loss, Surgical, Coagulation Disorder

VarmX B.V.

Phase 3

800

Porto

2026-08-18

Recruiting

A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

NCT07497087Systemic Sclerosis

Boehringer Ingelheim

Phase 3

448

Almada, Coimbra, Lisbon, Ponte de Lima, Porto

2026-07-27

Recruiting

DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

NCT07544654Extrapulmonary Neuroendocrine Cancer (epNEC)

DrugsObrixtamig·Etoposide·Carboplatin

Boehringer Ingelheim

Phase 3

390

Lisbon, Porto

2026-07-10

Recruiting

E-Mergir: A Digital Psychosexual Intervention for the Promotion of Mental and Sexual Health of Prostate Cancer Survivors

NCT07754929Prostate Cancer

Universidade do Porto

Not applicable

106

Porto

2026-07-01

Not yet open

Immediate Restoration of a New Implant With High Primary Stability

NCT07498556Dental Implants, Immediate Dental Implant Loading

Universidade do Porto

Not applicable

Porto

2026-07-01

Recruiting

Pridopidine Phase 3 Study in Huntington's Disease

NCT07609108Huntington Disease

DrugPridopidine

Prilenia

Phase 3

400

Coimbra, Lisbon, Porto, Torres Vedras

2026-07-01

Not yet open

Psoas Major Muscle Intervention on Chronic Lumbar Pain in Cleaning Professionals.

NCT07672197Lumbar Pain, Non-specific Low Back Pain (NSLBP)

Escola Superior de Tecnologia da Saúde do Porto

Not applicable

Porto

2026-07

Recruiting

A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

NCT07589634Multiple Myeloma

DrugsRamantamig·Tocilizumab

Janssen Research & Development, LLC

Phase 2

230

Braga, Lisbon, Porto, Vila Nova de Gaia

2026-06-30

Recruiting

Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients

NCT07507760Acute Myeloid Leukemia With Gene Mutations

DrugsDecitabine/Cedazuridine·Hydroxyurea·Ivosidenib·Cytarabine

PETHEMA Foundation

Phase 2

Aveiro, Funchal, Lisbon, Porto

2026-06-12

Not yet open

EMBRACE - From Vulnerable to Empowered: Implementation and Evaluation of a Multicomponent Program to Tackling Age-related Decline

NCT07628686Age-Related Cognitive Decline

University Fernando Pessoa

Not applicable

120

Porto

2026-06-01

Recruiting

A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction

NCT07192952Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)

DrugFinerenone

Bayer

Phase 3

117

Coimbra, Carnaxide, Lisbon, Porto

2026-06-01

Not yet open

Effects of an Osteopathic Manual Therapy Protocol on Heart Rate Variability, Stress, and Anxiety in Young Adults

NCT07670806Stress, Anxiety

Escola Superior de Tecnologia da Saúde do Porto

Not applicable

Porto

2026-06

Not yet open

Effect of Osteopathic Technique on Maximum Mouth Opening Width, Masseter Muscle Tone and Stiffness

NCT07670832Asymptomatic Condition

Escola Superior de Tecnologia da Saúde do Porto

Not applicable

Porto

2026-06

Recruiting

A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

NCT07525206Colorectal Cancer

DrugsTelisotuzumab Adizutecan·Trifluridine/Tipiracil·Bevacizumab

AbbVie

Phase 3

990

Guimarães, Loures, Almada, Lisbon, Porto

2026-05-22

Recruiting

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

NCT07413939HER2-positive Breast Cancer

DrugsZN-A-1041·Tucatinib·Trastuzumab·Capecitabine

Hoffmann-La Roche

Phase 2/3

650

Amadora-Lisbon, Lisbon, Loures, Matosinhos Municipality, Porto, Vila Nova de Gaia

2026-05-21

Active, closed

AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

NCT07400107Obesity, Overweight, Diabetes Mellitus, Type 2

DrugsNNC0487-0111·Semaglutide

Novo Nordisk A/S

Phase 3

985

Almada, Braga, Cascais, Lisbon, Porto, Senhora Da Hora, Matosinhos, Vila Nova de Gaia

2026-05-20

Recruiting

A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis

NCT07387549Primary Sclerosing Cholangitis

DrugElafibranor

Ipsen

Phase 3

350

Lisbon, Porto, Coimbra

2026-05-14

Active, closed

Effectiveness of the Self-Control Module of a Positive Mental Health Promotion Programme for Adult Informal Caregivers of People With Dementia: Protocol for a Randomised Controlled Trial

NCT07577440Mental Health

University Rovira i Virgili

Not applicable

108

Porto

2026-05-03

Recruiting

Augmented Reality-Based Binocular Therapy for Visual Rehabilitation in Adults With Amblyopia

NCT07819552Amblyopia, Anisometropic Amblyopia

Polytechnic Institute of Porto

Not applicable

Coimbra, Porto

2026-05-01

Not yet open

Study of Hyaluronic Acid Used With Gum Surgery to Treat Gum Recession in Adults

NCT07529340Gingival Recession, Mucogingival Surgery

Universidade do Porto

Not applicable

Porto

2026-05

Not yet open

Home Monitoring in eAMD Treatment

NCT07340372Exudative Age-Related Macular Degeneration

DrugAflibercept

Association for Innovation and Biomedical Research on Light and Image

Observational

Coimbra, Leiria, Lisbon, Loures, Porto

2026-05

Recruiting

Leica Microsystems Sponsored PMCF Study to Collect and Confirm Clinical Data on the Performance of the GLOW400 Device When Used in Accordance With Its Intended Use

NCT07366892Suspected Grade III and IV Gliomas Requiring Surgical Intervention, Neurosurgical Procedure, Glioma, Glioblastoma (GBM)

Leica Microsystems (Schweiz) AG

Observational

Porto

2026-04-28

Recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD

NCT07285655Pulmonary Hypertension Due to Lung Disease (Disorder)

Liquidia Technologies, Inc.

Phase 3

344

Almada, Coimbra, Porto

2026-04-23

Recruiting

An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)

NCT07365332Pulmonary Arterial Hypertension

Inhibikase Therapeutics

Phase 3

486

Porto

2026-04-23

Recruiting

A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

NCT07546500Ovarian Cancer

DrugAzenosertib

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

Phase 3

420

Coimbrã, Lisbon, Porto

2026-04-17

Recruiting

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

NCT07472517Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)

DrugsObrixtamig·Etoposide·Atezolizumab·Carboplatin

Boehringer Ingelheim

Phase 3

670

Braga, Coimbra, Lisbon, Porto

2026-04-13

By invitation

Porcine Derma for Soft Tissue Augmentation Around Implants

NCT07436091Soft Tissue Augmentation Around Dental Implants

Universidade do Porto

Not applicable

Porto

2026-04-01

Recruiting

InRAD Observational Study

NCT07213700Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD), Non-Alzheimer Degenerative Dementia

Stichting International Registry for Alzheimer's Disease and other Dementias Foundation

Observational

50,000

Porto

2026-03-30

Recruiting

Mobile App vs. In-Person Pelvic Floor Rehabilitation for Urinary Leakage in Adult Women

NCT07597174Urinary Incontinence , Stress

Unidade Local de Saúde São João, Oporto

Not applicable

Porto

2026-03-26

Recruiting

A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

NCT07326709Huntington Disease

DrugVotoplam

Novartis Pharmaceuticals

Phase 3

770

Lisbon, Porto

2026-03-24

Recruiting

PRIMARY-HF: Heart Failure Screening in Primary Care Using Point-of- Care

NCT07711821Heart Failure

Universidade do Porto

Not applicable

160

Amadora, Lisbon, Porto

2026-03-23

Recruiting

A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT

NCT07387367Adenovirus Infections

SymBio Pharmaceuticals

Phase 3

180

Lisbon, Porto

2026-03-17

Recruiting

ipRGC as a Potential Biomarker for Predicting Transcranial Magnetic Stimulation Treatment Response in Major Depressive Disorder

NCT07474974Depression - Major Depressive Disorder, Treatment Resistant Depression

Polytechnic Institute of Porto

Not applicable

Porto

2026-03-15

Active, closed

An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps

NCT07424144Chronic Rhinosinusitis With Nasal Polyps

DrugItepekimab

Sanofi

Phase 3

Guimarães, Porto

2026-03-12

Active, closed

Expert Validation of an Autonomous Personalized Physical Activity Algorithm

NCT07475221Experts in Physical Activity Prescription and Risk Health Screening

Polytechnic Institute of Porto

Observational

Porto

2026-03-10

Recruiting

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

NCT07438496Lupus Erythematosus, Systemic

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

600

Almada, Lisbon, Ponte de Lima, Porto, Vila Nova de Gaia

2026-03-05

Recruiting

To Evaluate the Feasibility and Safety of Combining Surgery (Pancreatectomy and Cytoreduction) With HIPEC for Treating Pancreatic Cancer With Peritoneal Involvement.

NCT07493421Pancreatic Adenocarcinoma, Peritoneal (Metastatic) Cancer

Unidade Local de Saúde São João, Oporto

Not applicable

Lisbon, Porto

2026-03-01

Not yet open

Suprascapular Nerve Block to Improve Tolerance and Outcomes of Shoulder Hydrodistension in Adhesive Capsulitis

NCT07380087Adhesive Capsulitis, Adhesive Capsulitis of Unspecified Shoulder, Adhesive Capsulitis, Shoulder, Frozen Shoulder

Universidade do Porto

Not applicable

Porto

2026-03-01

Active, closed

Evaluating the Mentalization-based Treatment Lighthouse Parenting Programme: Protocol of a Feasibility and Acceptability Quasi-Experimental Study

NCT07448870Being Referred for Child Protection Services

Universidade do Porto

Not applicable

Porto

2026-03-01

Recruiting

Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis. MM09-SIT-063.

NCT07904052Allergic Rhinitis, Allergic Rhinoconjunctivitis, Allergic Asthma

DrugEP-088_MM09

Inmunotek S.L.

Phase 3

250

Coimbra, Lisbon, Porto

2026-02-24

Recruiting

Multicomponent Exercise Program on Physical Function, Cognition and Falls Risk Among Older Adults Living in Nursing Homes (MOVE4CARE)

NCT07392944Frailty, Dementia

Universidade do Porto

Not applicable

Porto

2026-02-18

Recruiting

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

NCT07220083Focal Segmental Glomerulosclerosis

DrugApecotrep

Boehringer Ingelheim

Phase 3

286

Almada, Amadora, Braga, Coimbra, Lisbon, Loures, Porto, Setúbal

2026-02-16

Recruiting

A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)

NCT07202546HIV Infections

DrugsVH4524184·Dovato·Dolutegravir/Lamivudine

ViiV Healthcare

Phase 2

186

Porto, Vila Nova de Gaia

2026-02-11

Recruiting

A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

NCT07222332Diabetes Mellitus, Type 1

DrugBaricitinib

Eli Lilly and Company

Phase 3

300

Braga, Porto, Viana do Castelo, Vila Nova de Gaia

2026-02-05

Recruiting

TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

NCT07223203Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy, hATTR-PN

DrugsNucresiran·Vutrisiran

Alnylam Pharmaceuticals

Phase 3

125

Lisbon, Porto

2026-02-03

Not yet open

Evaluating the Impact of In-Situ Simulation on Interprofessional Healthcare Team Training

NCT07346937in Situ Simulation, Simulation in Training Center

Universidade do Porto

Not applicable

108

Matosinhos Municipality, Porto

2026-02

Recruiting

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

NCT07262619Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Colorectal Cancer

DrugsKeytruda·Pembrolizumab

Eikon Therapeutics

Phase 1/2

160

Lisbon, Loures, Porto

2026-01-20

Recruiting

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

NCT07195695Non-small Cell Lung Cancer

DrugsZongertinib·Atezolizumab·Durvalumab·Nivolumab

Boehringer Ingelheim

Phase 3

400

Lisbon, Porto

2026-01-16

Recruiting

PERFECT - Portuguese Evolut Registry Studying the Outcomes of Medtronic Evolut™ FX+ TAVI System by Evaluating an Optimal Care Pathway for TAVI

NCT07343674Severe Symptomatic Aortic Stenosis (Defined as New York Heart Association (NYHA) Class ≥ II)

Portuguese Association of Interventional Cardiology

Observational

500

Coimbra, Lisbon, Funchal, Porto, Vila Nova de Gaia, Evora

2026-01-14

Recruiting

A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

NCT07222137Diabetes Mellitus, Type 1

DrugBaricitinib

Eli Lilly and Company

Phase 3

150

Braga, Matosinhos Municipality, Porto, Viana do Castelo, Vila Nova de Gaia

2026-01-12

Recruiting

Assessing Agreement Between Acuvera Capture and Paper-Based Methods for BCVA Data Recording in Ophthalmic Trials

NCT07613580Ophthalmopathy

OptymEdge, LLC

Observational

Coimbra, Porto

2026-01-12

Recruiting

Leica Microsystems Sponsored Study to Collect and Confirm Clinical Data on the Performance of the GLOW800 Device When Used in Accordance With Its Intended Use.

NCT07164040Reconstructive Surgical Procedures, Plastic Surgery, Vascular Surgical Procedure, Cerebrovascular Disorder

Leica Microsystems (Schweiz) AG

Observational

Porto

2026-01-08

Recruiting

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

NCT07253285Overweight, Obesity

DrugsCagrilintide·Semaglutide

Novo Nordisk A/S

Phase 3

460

Porto, Vila Nova de Gaia

2026-01-08

Recruiting

Care4mommies in Action: A Compassion-based Intervention

NCT07611175Pregnancy Related

Portucalense University

Not applicable

Porto

2026-01-02

Not yet open

Effects of an Elastic Band Warm-Up on Sprint and Vertical Jump Performance in Female Football Players

NCT07316881Physical Performance Parameters

University Institute of Maia

Not applicable

Porto

2026-01

Recruiting

A Study to Investigate Bowel Cleansing With PLENVU® Compared to Sodium Picosulfate in Participants Aged 1 to < 18 Years of Age in Preparation for Colonoscopy

NCT07218523Bowel Cleansing Prior to Clinical Procedures

DrugsPicoprep·Plenvu

Norgine

Phase 3

212

Braga, Coimbra, Lisbon, Porto

2025-12-29

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

NCT07155187Non-Small Cell Lung Cancer, c-MET

DrugsTelisotuzumab Adizutecan·Osimertinib

AbbVie

Phase 2/3

490

Guimarães, Loures, Senhora da Hora, Braga, Porto

2025-12-10

Active, closed

A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

NCT07107945Chronic Kidney Disease

DrugDapagliflozin

Boehringer Ingelheim

Phase 3

135

Coimbra, Lisbon, Porto

2025-12-09

Not yet open

Acute Cardiovascular and Neuromuscular Responses to Walking With Blood Flow Restriction (BFR) in Older Adults

NCT07275138Healthy Older Adults

Universidade da Coruña

Not applicable

Porto

2025-12-08

Recruiting

Virtual Reality for Recovery After Intensive Care (PICS)

NCT07585500Post-Intensive Care Syndrome (PICS), Critical Illness Recovery, Rehabilitation After Critical Illness, Rehabilitation Exercise of ICU Patients

University of Minho

Not applicable

Porto

2025-12-06

Recruiting

A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)

NCT07276724Severe Asthma

DrugGB-0895

Generate Biomedicines

Phase 3

786

Figueira da Foz Municipality, Porto

2025-12-03

Recruiting

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

NCT07276399Squamous Cell Carcinoma of Head and Neck

DrugsAmivantamab·Cisplatin·Carboplatin·Pembrolizumab

Janssen Research & Development, LLC

Phase 3

600

Lisbon, Portimão, Porto, Vila Nova de Gaia

2025-12-03

Recruiting

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

NCT07213674Metastatic Castration-resistant Prostate Cancer

DrugsXaluritamig·Cabazitaxel·Abiraterone acetate·Docetaxel

Amgen

Phase 3

750

Lisbon, Porto, Vila Nova de Gaia

2025-11-28

Recruiting

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer

NCT07278336Ovarian Cancer

DrugsBevacizumab·Carboplatin

AbbVie

Phase 1

285

Lisbon, Porto

2025-11-27

Active, closed

A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome

NCT07211685Alport Syndrome

Bayer

Phase 2

Vila Nova de Gaia, Torres Novas, Lisbon, Porto

2025-11-19

Recruiting

A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction

NCT07188805Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)

DrugFinerenone

Bayer

Phase 3

111

Coimbra, Lisbon, Carnaxide, Porto

2025-11-19

Recruiting

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo

NCT06804811NonSegmental Vitiligo

DrugRuxolitinib

Incyte Corporation

Phase 3

250

Coimbra, Lisbon, Porto

2025-11-13

Recruiting

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

NCT07225504Secondary Progressive Multiple Sclerosis (SPMS)

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

1,275

Braga, Lisbon, Porto

2025-11-11

Recruiting

Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

NCT06990269Geographic Atrophy Secondary to Age-related Macular Degeneration

ADARx Pharmaceuticals, Inc.

Phase 2

240

Coimbra, Porto

2025-11-10

Recruiting

Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

NCT07007065Neovascular Age-related Macular Degeneration

DrugSurabgene Lomparvovec

AbbVie

Phase 3

561

Coimbra, Lisbon, Porto

2025-11-05

Recruiting

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

NCT07085767Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer

DrugsPalazestrant·Ribociclib·Letrozole

Olema Pharmaceuticals, Inc.

Phase 3

1,000

Coimbra, Lisbon, Porto

2025-11-03

Recruiting

Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

NCT06659445Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)

DrugAvacincaptad Pegol

ONL Therapeutics

Phase 2

324

Coimbra, Gaia, Porto

2025-10-28

Recruiting

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT06793215Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer

DrugsDivarasib·Pemetrexed·Cisplatin·Carboplatin

Hoffmann-La Roche

Phase 3

600

Braga, Loures, Porto, Vila Nova de Gaia

2025-10-24

Recruiting

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

NCT06899126Non-small Cell Lung Cancer

DrugsTrastuzumab deruxtecan·Pemetrexed·Keytruda·Pembrolizumab

Daiichi Sankyo

Phase 3

686

Lisbon, Porto

2025-10-24

Recruiting

A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A

NCT07220564Haemophilia A

Novo Nordisk A/S

Phase 1

Porto

2025-10-23

Active, closed

Mixed Reality vs. Traditional Arthroscopic Simulation

NCT07648056Surgical Education, Clinical Competence

Universidade da Coruña

Not applicable

Porto

2025-10-20

Recruiting

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

NCT07196722Crohn Disease

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 2/3

1,092

Braga, Guimarães, Lisbon, Loures, Porto

2025-10-03

Recruiting

BioNortHealth Project

NCT07833787College Students

Polytechnic Institute of Porto

Observational

1,500

Porto

2025-10-01

Active, closed

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

NCT07196748Colitis, Ulcerative

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

896

Braga, Guimarães, Lisbon, Loures, Porto, Viana do Castelo

2025-10-01

Recruiting

Psychodrama Group Therapy for Breakup Distress and Relationship Adjustment: A Randomized Trial

NCT07658248Breakup Distress, Dyadic Adjustment

Universidade do Porto

Not applicable

Porto

2025-09-23

Recruiting

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

NCT07190209Chronic Obstructive Pulmonary Disease

DrugLunsekimig

Sanofi

Phase 3

942

Almada, Braga, Guimarães, Matosinhos Municipality, Porto

2025-09-16

Recruiting

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

NCT06926868Breast Neoplasms

DrugsIza-bren·Nab-paclitaxel·Capecitabine·Gemcitabine

Bristol-Myers Squibb

Phase 2/3

600

Lisbon, Coimbra, Porto

2025-09-11

Not yet open

Tailored Vs. Empirical Helicobacter Pylori Infection Treatment

NCT06200779Helicobacter Pylori Infection

Manuel Coelho da Rocha

Phase 4

160

Porto

2025-09

Recruiting

A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

NCT06920004Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy

DrugsEmpasiprubart·IVIG

argenx

Phase 3

218

Porto

2025-08-22

Recruiting

Study to Investigate the Efficacy, Safety and Durability of Faricimab in Caucasian Patients With Polypoidal Choroidal Vasculopathy (MONDEGO)

NCT06709339Polypoidal Choroidal Vasculopathy

DrugsVabysmo·Faricimab

Association for Innovation and Biomedical Research on Light and Image

Phase 4

120

Coimbra, Leiria, Lisbon, Loures, Porto

2025-08-06

Recruiting

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

NCT07005102Non-Squamous Non-Small Cell Lung Cancer, c-MET

DrugsTelisotuzumab Adizutecan·Osimertinib·Pemetrexed·Cisplatin

AbbVie

Phase 2/3

854

Braga, Porto

2025-08-03

Active, closed

A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 Interferonopathies

NCT06878365Type 1 Interferonopathies

Boehringer Ingelheim

Phase 1

Lisbon, Porto

2025-07-29

Recruiting

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

NCT06757634Breast Cancer

DrugsGedatolisib·Ribociclib·Palbociclib·Letrozole

Celcuity Inc

Phase 3

1,180

Coimbra, Lisbon, Porto

2025-07-24

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

NCT06953960Multiple Myeloma

DrugsEtentamig·Pomalidomide·Daratumumab·Dexamethasone

AbbVie

Phase 1/2

325

Lisbon, Braga, Porto

2025-07-23

Recruiting

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

NCT06976203Alzheimer's Disease

DrugsKarX-EC·KarXT

Bristol-Myers Squibb

Phase 3

586

Torres Vedras, Matosinhos Municipality, Braga, Coimbra, Guimarães, Porto

2025-07-21

Recruiting

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive

DrugsNeladalkib·Alectinib

Nuvalent Inc.

Phase 3

450

Alcabideche, Lisbon, Porto

2025-07-17

Active, closed

DanceOn50+: Effects of a Dance Program on Physical and Psycho-emotional Health

NCT07158866Physical Activity, Physical Fitness, Well Being

Universidade do Porto

Not applicable

110

Porto

2025-07-15

Active, closed

A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG

NCT06892288Phosphomannomutase 2 Deficiency, PMM2-CDG

Glycomine, Inc.

Phase 2/3

Porto

2025-07-09

Recruiting

Single-Fraction Very Accelerated Partial Breast Irradiation (sfVAPBI)

NCT07067437Breast Neoplasms

National Institute of Oncology, Hungary

Not applicable

250

Porto

2025-07-01

Recruiting

Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype

NCT06486883Advanced Breast Cancer, Advanced Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma

DrugsCDK4/6i·Trastuzumab deruxtecan

MedSIR

Phase 2

200

Lordelo, Alcabideche, Amadora, Aveiro, Braga, Lisbon, Loures, Porto

2025-06-30

Recruiting

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms

DrugsEpirubicin·Adriamycin·Xeloda·Paraplatin

Merck Sharp & Dohme LLC

Phase 3

2,400

Lisbon, Porto

2025-06-30

Active, closed

Preliminary Efficacy of AdoptMindful2Care: A Mindful Parenting Post-adoption Intervention for Adoptive Parents

NCT07043660Parenting Stress

University of Coimbra

Not applicable

Aveiro, Coimbra, Lisbon, Porto

2025-06-30

Recruiting

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)

NCT07082725Niemann-Pick Type C Disease

DrugNizubaglustat

Azafaros B.V.

Phase 3

Porto

2025-06-30

Recruiting

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis

NCT07054515Niemann-Pick Type C Disease, GM1 Gangliosidosis, GM2 Gangliosidosis

DrugNizubaglustat

Azafaros B.V.

Phase 3

147

Porto, Lisbon

2025-06-30

Active, closed

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 Gangliosidosis

NCT07082543Gangliosidoses, GM2, Gangliosidosis, GM1

DrugNizubaglustat

Azafaros B.V.

Phase 3

Porto, Lisbon

2025-06-30

By invitation

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa

NCT07007637Hidradenitis Suppurativa

DrugSonelokimab

MoonLake Immunotherapeutics AG

Phase 3

835

Lisbon, Porto

2025-06-27

Recruiting

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity

DrugMaridebart cafraglutide

Amgen

Phase 3

5,056

Almada, Coimbra, Guimarães, Lisbon, Matosinhos Municipality, Porto, Vila Nova de Gaia

2025-06-25

Recruiting

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

NCT06872892Bronchiectasis

DrugVerducatib

Boehringer Ingelheim

Phase 3

1,755

Aveiro, Braga, Coimbra, Guimarães, Leiria, Lisbon, Porto

2025-06-09

Recruiting

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT06852222Leukemia, Myeloid, Acute

DrugsBleximenib·Azacitidine·Venetoclax

Janssen Research & Development, LLC

Phase 3

600

Lisbon, Porto

2025-06-04

Recruiting

Early Doppler-Assisted Mobilization in Adults After Acute Ischemic Stroke

NCT07232498Arterial Ischemic Stroke

Unidade Local de Saúde de Coimbra, EPE

Not applicable

1,300

Coimbra, Lisbon, Porto

2025-06-04

Active, closed

A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy

NCT06821542Chronic Graft-versus-host-disease

DrugAxatilimab

Incyte Corporation

Phase 3

Lisbon, Porto

2025-06-04

Recruiting

Overweight and Obesity in Adolescents - Sleep Behavioral Intervention

NCT07255274Obesity and Overweight, Sleep Disorder

University of Beira Interior

Not applicable

126

Covilha, Porto

2025-06-03

Recruiting

LDL Cholesterol Reduction Following Ezetimibe Initiation

NCT07839741Atherosclerotic Cardiovascular Disease (ASCVD), Cardiovascular Risk, LDL Cholesterol

DrugEzetimibe

Universidade do Porto

Phase 4

100

Porto

2025-06-01

Recruiting

Mediterranean Diet Intervention for Maternal Postpartum

NCT07038681Postpartum, Cardiometabolic Factors, Cardiac Reverse Remodeling

Universidade do Porto

Not applicable

Porto

2025-05-31

Recruiting

Study on Safety and Performance of AdvanCore Bone Void Filler

NCT06736457Bone Fractures, Bone Defects, Bone Loss, Bone Graft

Artur Salgado SA

Not applicable

190

Guimarães, Porto, Tomar, Lordelo

2025-05-29

Active, closed

A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)

NCT06961006Malignant Melanoma

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 2

160

Lisbon, Porto

2025-05-29

Recruiting

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

DrugsZolbetuximab·Adrucil·Capecitabine·Oxaliplatin

Astellas Pharma Global Development, Inc.

Phase 3

500

Almada, Braga, Guimarães, Lisbon, Porto

2025-05-22

Recruiting

Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation

NCT06830798Delayed Graft Function, DGF, Kidney Transplant

DrugRavulizumab

Alexion Pharmaceuticals, Inc.

Phase 3

450

Lisbon, Porto

2025-05-19

By invitation

A Multicenter Study to Optimize Microembolic Signal Classification Based on Double--Blind Multiparametric Assessment by Human Experts Using an Universal Graphical Interface [MESOMEGA]

NCT07172165Microemboli, Stroke, Transcranial Doppler Ultrasound

Universidade do Porto

Observational

850

Porto

2025-05-15

Recruiting

Portuguese Registry With Meril Myval THV Series - MyPORTuVal Registry

NCT06818435Aortic Valve Stenosis, TAVI(Transcatheter Aortic Valve Implantation)

Portuguese Association of Interventional Cardiology

Observational

150

Carnaxide, Coimbra, Evora, Lisbon, Porto

2025-05-13

Recruiting

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

NCT06563895Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies

DrugAcoramidis

Eidos Therapeutics, a BridgeBio company

Phase 3

587

Lisbon, Porto

2025-05-12

Recruiting

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

NCT06819891Moderately to Severely Active Crohns Disease

DrugAfimkibart

Hoffmann-La Roche

Phase 3

425

Braga, Lisbon, Porto, Santa Maria da Feira, Viseu

2025-05-12

Recruiting

Combining Noninvasive Brain Stimulation and Augmented Reality-based Dichoptic Therapy for Treating Amblyopic Adults

NCT07752433Amblyopia, Anisometropic Amblyopia

Polytechnic Institute of Porto

Not applicable

Coimbra, Porto

2025-05-01

By invitation

ESCAPE10: Epidemiology, Risk Factors, and Outcomes of Severe Community-acquired Pneumonia in Elderly Patients Acquired Pneumonia in Elderly Patients

NCT07070284Severe Community-Acquired Pneumonia (sCAP), Elderly Infection, Community-Acquired Infections, Health Care Quality, Access, and Evaluation

Joan Sabater-Riera

Observational

500

Porto

2025-05-01

Not yet open

Clinical Impact of a Digital Home-based Falls Prevention Program on Elderly People

NCT03750500Fall

Sword Health, SA

Not applicable

100

Porto

2025-05

Not yet open

Determinants of the Nutritional Composition of Donor Human Milk

NCT06904924Human Milk Nutrition

Universidade do Porto

Observational

Porto

2025-05

Recruiting

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

NCT06875310Carcinoma, Non-Small-Cell Lung

DrugsAdagrasib·Pemetrexed·Keytruda·Cisplatin

Mirati Therapeutics Inc.

Phase 3

630

Lisbon, Coimbra, Porto

2025-04-24

Active, closed

A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

NCT06934226Plaque Psoriasis

DrugsIcotrokinra·Ustekinumab

Janssen Research & Development, LLC

Phase 3

752

Guimarães, Leiria, Lisbon, Porto

2025-04-15

Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

NCT06868277Carcinoma, Non-Small Cell Lung

DrugsRilvegostomig·Keytruda·Pembrolizumab

AstraZeneca

Phase 3

830

Alcabideche, Braga, Coimbra, Lisbon, Loures, Matosinhos Municipality, Porto

2025-04-10

Recruiting

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

NCT06824467Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

DrugsSteroid mouthwash (dexamethasone·Mvasi·Acetaminophen·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

770

Lisbon, Porto

2025-04-09

Recruiting

Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

NCT06408259Multiple Sclerosis, Relapsing-Remitting

DrugsFingolimod·Ozanimod

Bristol-Myers Squibb

Phase 3

194

Braga, Coimbra, Lisbon, Porto

2025-04-08

Recruiting

Effect of Patiromer in Children Under 12 Years of Age With High Blood Potassium Levels

NCT05766839Hyperkalemia

DrugPatiromer

Vifor Pharma, Inc.

Phase 2

Porto

2025-04-06

Active, closed

Fiability of a Telerehabilitation Programme Based on the Neurodevelopmental Treatment (NDT) Model on Gross Motor Function and Functional Performance in Children With Cerebral Palsy.

NCT07394985Cerebral Palsy Children

Escola Superior Saúde Fernando Pessoa

Not applicable

Porto

2025-04-04

Recruiting

Efficacy and Safety of SLIT in Patients With Rhinitis/RC With/Without Mild-moderate Asthma, Due to Dpt and/or Df

NCT07348302Rhinitis, Rhinoconjunctivitis

Inmunotek S.L.

Phase 3

736

Porto, Santarém

2025-04-02

Recruiting

Intervention Project to Increase Adherence to Colorectal Cancer Screening in Barcelos/Esposende

NCT06972160Colon and Rectal Cancer

Local Health Unit Barcelos/Esposende, Public Health Unit

Not applicable

1,038

Porto

2025-04-01

Not yet open

Effectiveness of Early Intervention in Palliative Care for Acute Myeloid Leukemia Patients Comparing to Standard of Care

NCT06848270Palliative Care, Acute Myeloid Leukaemia

Universidade do Porto

Not applicable

Porto

2025-04-01

Not yet open

Investigation of the Mechanisms of the Gut-brain Axis in Binge Eating and Obesity.

NCT06823557Binge Eating Disorder, Obesity

Universidade do Porto

Phase 1

104

Porto

2025-04

Recruiting

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

NCT06890598Carcinoma, Non-Small-Cell Lung

DrugsOlomorasib·Durvalumab·Pembrolizumab

Eli Lilly and Company

Phase 3

700

Coimbra, Lisbon, Porto

2025-03-27

Active, closed

Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

NCT06726265Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

DrugsEfti·Pemetrexed·Keytruda·Paclitaxel

Immutep S.A.S.

Phase 3

756

Almada, Lisbon, Loures, Porto

2025-03-21

Recruiting

A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

NCT06819878Moderately to Severely Active Crohns Disease

DrugAfimkibart

Hoffmann-La Roche

Phase 3

600

Braga, Lisbon, Porto, Santa Maria da Feira, Viseu

2025-03-17

Recruiting

Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake

NCT06571149Ischemic Stroke

DrugsAlteplase·Tenecteplase

Insel Gruppe AG, University Hospital Bern

Phase 4

906

Amadora, Coimbra, Funchal, Lisbon, Matosinhos Municipality, Porto

2025-03-14

Recruiting

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

NCT06615479Relapsed or Refractory Multiple Myeloma (RRMM)

DrugsArlo-cel·Carfilzomib·Pomalidomide·Daratumumab

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 3

440

Porto

2025-03-12

Recruiting

Algae Effects in Markers of Cardiovascular Risk and Gut Microbiome

NCT07173062Stroke, Coronary Arterial Disease (CAD), Myocardial Infarction (MI), Diabetes Mellitus

Universidade do Porto

Not applicable

150

Porto

2025-03-11

By invitation

Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0

NCT06823115Acute Kidney Injury, Fluid Overload, Prematurity Complications, Risk Factors

Indiana University

Observational

8,000

Coimbra, Lisbon, Porto

2025-03-01

Not yet open

Prehabilitation for Lung Cancer Patients Undergoing Lung Resection

NCT06802627Lung Cancer, Lung Resection

Universidade do Porto

Not applicable

200

Porto

2025-03-01

Recruiting

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

NCT06767514Non-Small Cell Lung Cancer

DrugsIvonescimab·Pembrolizumab

Summit Therapeutics

Phase 3

780

Braga, Lisbon, Porto, Coimbra, Faro

2025-02-27

Recruiting

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

NCT06731478Gastric Cancer, Gastroesophageal Junction Cancer

DrugsTrastuzumab deruxtecan·Trastuzumab·Keytruda·Pembrolizumab

Daiichi Sankyo

Phase 3

726

Braga, Guimarães, Lisbon, Porto

2025-02-27

Recruiting

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

NCT06810505Chronic Migraine

DrugAtogepant

AbbVie

Phase 3

420

Lisbon, Almada, Coimbra, Porto

2025-02-13

Active, closed

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

NCT06834347Chronic Rhinosinusitis With Nasal Polyps

DrugsItepekimab·Mometasone furoate

Sanofi

Phase 3

231

Guimarães, Matosinhos Municipality, Porto, Santa Maria da Feira

2025-02-12

By invitation

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)

NCT06908226Developmental and Epileptic Encephalopathy

DrugBexicaserin

Longboard Pharmaceuticals

Phase 3

324

Coimbra, Lisbon, Porto

2025-02-12

Active, closed

Evaluating the Efficacy of a New Sexual Violence Prevention Program With College Students

NCT06887361Sexual Violence

Universidade do Porto

Not applicable

200

Porto

2025-02-10

Active, closed

Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

NCT06806293Menstrual Migraine (MM)

DrugAtogepant

AbbVie

Phase 3

468

Guimarães, Lisbon, Loures, Senhora da Hora, Almada, Aveiro, Braga, Porto

2025-02-10

Active, closed

A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity

NCT06780449Obesity

DrugsCagrilintide·Semaglutide

Novo Nordisk A/S

Phase 3

400

Senhora Da Hora, Matosinhos, Lisbon, Porto, Vila Nova de Gaia

2025-02-10

Recruiting

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum

NCT06624670Pyoderma Gangrenosum

DrugsSpesolimab·Prednisolone·Prednisone

LEO Pharma

Phase 3

Coimbra, Lisbon, Porto

2025-02-05

Active, closed

A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)

NCT06680817Neovascular Age-related Macular Degeneration, Diabetic Macular Edema

DrugsVabysmo·Faricimab

Hoffmann-La Roche

Observational

875

Coimbra, Lisbon, Porto

2025-02-05

Recruiting

Long-term Evaluation of the SIMEOX Device at Home in Non-cystic Fibrosis Bronchiectasis

NCT06487273Non-cystic Fibrosis Bronchiectasis

Physio-Assist

Not applicable

468

Braga, Creixomil, Porto

2025-02-03

Active, closed

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

NCT06799000Hidradenitis Suppurativa

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

588

Almada, Braga, Coimbra, Lisbon, Porto

2025-01-31

Not yet open

Early Warning System for Allergic Rhinitis in the MASK-air® App

NCT06768736Allergic Rhinitis

Universidade do Porto

Not applicable

210

Porto

2025-01-30

Recruiting

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma

DrugsFicerafusp alfa·Keytruda·Pembrolizumab

Bicara Therapeutics

Phase 2/3

650

Braga, Coimbra, Lisbon, Portimão, Porto, Senhora da Hora, Vila Nova de Gaia

2025-01-28

Recruiting

Nutrition-based Interventions to Prevent Cognitive Decline

NCT06853405Cognitive Dysfunction, Cognition Disorder, Memory Disorders, Cognitive Impairment

Instituto de Saude Publica da Universidade do Porto

Not applicable

120

Porto

2025-01-27

Recruiting

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

NCT06717347Diffuse Large B-Cell Lymphoma

DrugsRituximab Biosimilar·Zilovertamab vedotin·Riabni·Ruxience

Merck Sharp & Dohme LLC

Phase 3

1,046

Braga, Lisbon, Porto

2025-01-27

Recruiting

A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease

NCT06100289Ulcerative Colitis, Crohn's Disease

DrugVedolizumab

Takeda

Phase 3

Coimbra, Lisbon, Porto

2025-01-22

Active, closed

Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis

NCT06846541Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis

Alumis Inc

Phase 3

1,680

Guimarães, Lisbon, Porto

2025-01-08

Not yet open

Optimal Articular Solutions With Intraosseous and Synovial Platelet-Rich Plasma

NCT06520059Knee Osteoarthritis

Universidade do Porto

Phase 4

Porto

2025-01-01

Active, closed

A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)

NCT06687369Non Squamous Non Small Cell Lung Cancer

DrugsEU sourced Keytruda·US-sourced Keytruda·Pemetrexed·Cisplatin

mAbxience Research S.L.

Phase 3

726

Lisbon, Matosinhos Municipality, Porto

2024-12-30

Active, closed

A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)

NCT06593522MTAP-deleted NSCLC

DrugAnvumetostat

Amgen

Phase 2

Braga, Lisbon, Porto

2024-12-26

Recruiting

A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

NCT06500702Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion

DrugsBrivekimig·Frexalimab·Rilzabrutinib

Sanofi

Phase 2

Carnaxide, Lisbon, Porto

2024-12-19

Active, closed

A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy

NCT06742190Multifocal Motor Neuropathy (MMN), MMN

DrugsEmpasiprubart·Immunoglobulin·IVIG

argenx

Phase 3

154

Porto

2024-12-18

Recruiting

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT06667076Carcinoma, Non-Small-Cell Lung

DrugsLazertinib·Amivantamab

Janssen Research & Development, LLC

Phase 2

480

Braga, Guimarães, Lisbon, Loures, Porto, Vila Nova de Gaia

2024-12-16

Active, closed

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06588855Moderately to Severely Active Ulcerative Colitis

DrugAfimkibart

Hoffmann-La Roche

Phase 3

350

Braga, Lisbon, Portimão, Porto, Santa Maria da Feira, Viseu

2024-12-11

Recruiting

Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

NCT06597019Familial Hypercholesterolemia - Heterozygous

DrugInclisiran

Novartis Pharmaceuticals

Phase 3

Coimbra, Lisbon, Porto

2024-12-09

Recruiting

Improving Learning and Memory in Portuguese Patients With Multiple Sclerosis

NCT06723444Multiple Sclerosis

Centro Hospitalar De São João, E.P.E.

Not applicable

Porto

2024-12-05

By invitation

A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

NCT06679946Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

DrugVutrisiran

Alnylam Pharmaceuticals

Phase 3

700

Creixomil, Lisbon, Porto, Viseu

2024-12-03

Recruiting

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

NCT06472245Patients With Non-Small Cell Lung Cancer

DrugsTedopi·Docetaxel

OSE Immunotherapeutics

Phase 3

363

Coimbra, Lisbon, Porto, Vila Nova de Gaia

2024-12-03

Active, closed

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

NCT06694805HIV Infections

DrugsRpv La·Cabotegravir·B/F/TAF

ViiV Healthcare

Phase 3

326

Porto

2024-12-02

Active, closed

Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine

NCT06543914Migraine

AbbVie

Observational

1,314

Guimarães, Lisbon, Loures, Sintra, Torres Vedras, Coimbra, Porto

2024-11-26

Active, closed

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

NCT06635824PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC

DrugsDocetaxel·Pembrolizumab

Genmab

Phase 3

191

Coimbra, Matosinhos Municipality, Porto, Setúbal

2024-11-25

Active, closed

Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

NCT06578247Leukemia

DrugQuizartinib

Daiichi Sankyo

Phase 3

700

Lisbon, Porto

2024-11-19

Recruiting

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

NCT06369285Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer

DrugAlisertib

Puma Biotechnology, Inc.

Phase 2

225

Lisbon, Porto

2024-11-19

Recruiting

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

NCT06672549Obesity, Overweight

DrugOrforglipron

Eli Lilly and Company

Phase 3

125

Lisbon, Porto

2024-11-18

Active, closed

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

NCT06719141Developmental and Epileptic Encephalopathy

DrugBexicaserin

Longboard Pharmaceuticals

Phase 3

367

Coimbra, Lisbon, Porto

2024-11-11

Recruiting

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

NCT06663332Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile

DrugGuselkumab

Janssen Research & Development, LLC

Phase 3

196

Braga, Porto

2024-10-29

Recruiting

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

NCT06561386Non-small Cell Lung Cancer

DrugsRelatlimab·Pemetrexed·Nivolumab·Cisplatin

Bristol-Myers Squibb

Phase 3

1,000

Lisbon, Coimbra, Porto

2024-10-07

By invitation

Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients

NCT06657859Pmm2-CDG, Phosphomannomutase 2 Deficiency

Glycomine, Inc.

Phase 2

Porto

2024-09-30

Active, closed

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

NCT06492616Breast Cancer

DrugsElacestrant·Tamoxifen·Exemestane·Anastrozole

Stemline Therapeutics, Inc.

Phase 3

4,556

Loures, Vila Franca de Xira, Porto, Vila Nova de Gaia, Coimbra, Faro, Lisbon, Setúbal

2024-09-27

Active, closed

A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

NCT06660394Dravet Syndrome

DrugBexicaserin

Longboard Pharmaceuticals

Phase 3

108

Coimbra, Lisbon, Porto

2024-09-25

Active, closed

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

NCT06525220Head and Neck Squamous Cell Carcinoma

DrugsPetosemtamab·Pembrolizumab

Genmab

Phase 3

699

Coimbra, Lisbon, Portimão, Porto, Vila Real

2024-09-25

Active, closed

A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy

NCT06481891Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy

DrugSotagliflozin

Lexicon Pharmaceuticals

Phase 3

500

Braga, Faro, Lisbon, Porto

2024-09-24

Active, closed

A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06497556Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer

DrugsDivarasib·Adagrasib·Sotorasib

Hoffmann-La Roche

Phase 3

338

Braga, Coimbra, Lisbon, Porto

2024-09-23

Recruiting

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

NCT06635148Geographic Atrophy, Macular Degeneration

Janssen Research & Development, LLC

Phase 2/3

274

Coimbra, Porto

2024-09-19

Active, closed

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis

NCT06558279Myasthenia Gravis, Ocular

argenx

Phase 3

141

Lisbon, Porto

2024-09-18

Active, closed

A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06589986Moderately to Severely Active Ulcerative Colitis

DrugAfimkibart

Hoffmann-La Roche

Phase 3

400

Braga, Lisbon, Portimão, Porto, Santa Maria da Feira, Viseu

2024-09-17

Active, closed

A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)

NCT06616974Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction

Tectonic Therapeutic

Phase 2

191

Almada, Lisbon, Porto

2024-09-04

Recruiting

Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

NCT06274801Pulmonary Arterial Hypertension

Gossamer Bio USA, Inc.

Phase 3

330

Lisbon, Porto

2024-09-03

Recruiting

Distinct Exercise Modalities on Gut Microbiome

NCT06545123Sarcopenia, Older Adults

Faculty of Sports- Research Center in Physical Activity, Health and Leisure

Not applicable

Porto

2024-09-01

Recruiting

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

NCT06452277Advanced Non-small Cell Lung Cancer, HER2 Mutation

DrugsSevabertinib·Pemetrexed·Cisplatin·Carboplatin

Bayer

Phase 3

444

Coimbra, Matosinhos Municipality, Lisbon, Porto

2024-08-28

Active, closed

Volrustomig Priming Regimens Exploratory Phase II Platform Study

NCT06448754Non-small Cell Lung Cancer

DrugsVolrustomig·Ramucirumab·Pemetrexed·Paclitaxel

AstraZeneca

Phase 2

194

Lisbon, Porto

2024-08-27

Active, closed

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

NCT06461897Atopic Dermatitis

DrugsUpadacitinib·Dupilumab

AbbVie

Phase 3

699

Coimbra, Porto

2024-08-19

Active, closed

A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.

NCT06247995Breast Cancer

DrugsGa-NeoB·Lu-NeoB·Capecitabine

Novartis Pharmaceuticals

Phase 1/2

Porto

2024-08-14

Active, closed

A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT06508658Diffuse Large B-Cell Lymphoma

DrugsEpcoritamab·Lenalidomide·Rituximab·Oxaliplatin

Genmab

Phase 3

379

Lisbon, Porto

2024-08-13

Active, closed

A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME

NCT06571045Diabetic Macular Edema (DME)

DrugsRemigromig·Lucentis·Ranibizumab

EyeBiotech Ltd.

Phase 2/3

984

Coimbra, Porto

2024-08-07

Recruiting

"Breathlessness Diagnostics in a Box" (BiaB) for Primary Care. A Multi-country Quality Improvement Project Using a Randomized Stepped-wedge Design

NCT07320703Breathlessness, Cardiovascular, Pulmonary, Mental Disease

General Practitioners Research Institute

Not applicable

900

Porto

2024-08-05

Recruiting

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

NCT06380751Advanced Breast Cancer

DrugsSaruparib·Camizestrant·Exemestane·Anastrozole

AstraZeneca

Phase 3

788

Coimbra, Lisbon, Matosinhos Municipality, Porto, Vila Real

2024-08-01

Recruiting

Multicentre Study for Data Collection, Development, and Evaluation of Novel CRC Screening and Diagnostic Methods

NCT06515821Colorectal Cancer

Firalis SA

Observational

4,100

Porto

2024-08-01

Active, closed

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

NCT06517758Generalized Myasthenia Gravis

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

146

Lisbon, Porto, Vila Nova de Gaia

2024-07-31

Recruiting

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

NCT06559306Depressive Disorder, Major

DrugSeltorexant

Janssen Research & Development, LLC

Phase 3

752

Braga, Leiria, Lisbon, Loures, Ponta Delgada, Porto, Touguinho

2024-07-25

Recruiting

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

NCT06282575Biliary Tract Cancer

DrugsZanidatamab·Durvalumab·Gemcitabine·Cisplatin

Jazz Pharmaceuticals

Phase 3

286

Almada, Coimbra, Lisbon, Porto

2024-07-19

Active, closed

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

NCT06445023Chronic Spontaneous Urticaria

DrugBarzolvolimab

Celldex Therapeutics

Phase 3

963

Aveiro, Braga, Coimbra, Lisbon, Matosinhos Municipality, Porto, Setúbal, Vila Nova de Gaia

2024-07-11

Not yet open

Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab

NCT06371807Early Breast Cancer, Triple Negative Breast Cancer

DrugsCyclophosphamide·Paclitaxel·Carboplatin·Pembrolizumab

Fundacao Champalimaud

Phase 2

Lisbon, Porto

2024-07

Active, closed

A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus

NCT06015737Cutaneous Lupus Erythematosus

AstraZeneca

Phase 3

339

Braga, Lisbon, Porto

2024-06-29

Active, closed

A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06468228Hidradenitis Suppurativa

DrugLutikizumab

AbbVie

Phase 3

1,400

Guimarães, Lisbon, Porto

2024-06-27

Active, closed

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

NCT06496178Head and Neck Squamous Cell Carcinoma

DrugPetosemtamab

Genmab

Phase 3

621

Coimbra, Lisbon, Porto

2024-06-25

Recruiting

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

NCT06393374Triple-Negative Breast Cancer

DrugsXeloda·Sacituzumab tirumotecan·Keytruda·Capecitabine

Merck Sharp & Dohme LLC

Phase 3

1,530

Amadora, Lisbon, Porto

2024-06-24

Active, closed

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

NCT06356129Large B-cell Lymphoma

DrugsGolcadomide·Vincristine·Doxorubicin·Prednisone

Celgene

Phase 3

850

Lisbon, Porto

2024-06-19

Active, closed

A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)

NCT06411249Systemic Lupus Erythematosus

DrugBelimumab

GlaxoSmithKline

Phase 4

302

Almada, Lisbon, Porto

2024-06-06

Active, closed

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

NCT06211036Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer

DrugsTarlatamab·Durvalumab

Amgen

Phase 3

563

Lisbon, Matosinhos Municipality, Porto

2024-06-05

Active, closed

The Efficacy of the SUN Program in Adolescents

NCT06830278Sexual Violence

Universidade do Porto

Not applicable

231

Porto

2024-06-01

Not yet open

Screening Coronary Artery Disease Using artiFicial intelligencE in Non-contrast Computed Tomography

NCT06438393Coronary Artery Disease, Coronary Atheroscleroses

Universidade do Porto

Observational

1,000

Porto

2024-06

Recruiting

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

NCT06203210Small Cell Lung Cancer

DrugsAmrubicin·Ifinatamab Deruxtecan·Lurbinectedin·Topotecan

Daiichi Sankyo

Phase 3

540

Coimbra, Guimarães, Lisbon, Porto

2024-05-21

Recruiting

VE303 for Prevention of Recurrent Clostridioides Difficile Infection

NCT06237452Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection

Vedanta Biosciences, Inc.

Phase 3

852

Guimarães, Coimbra, Almada, Braga, Guarda, Porto, Vila Nova de Gaia

2024-05-20

Active, closed

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06158841Multiple Myeloma

DrugsElotuzumab·Etentamig·Carfilzomib·Selinexor

AbbVie

Phase 3

421

Lisbon, Porto

2024-05-19

Active, closed

Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma

NCT05739942Newly Diagnosed and Recurrent Glioblastoma

DrugsGa-NeoB·Lu-NeoB

Novartis Pharmaceuticals

Phase 1

Porto

2024-05-15

Active, closed

A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

NCT06407934Dermatitis Atopic

DrugAmlitelimab

Sanofi

Phase 3

1,541

Lisbon, Porto

2024-05-08

By invitation

A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE) (ENSEMBLE)

NCT06431893Homocystinuria

DrugPegtibatinase

Travere Therapeutics, Inc.

Phase 3

100

Coimbra, Lisbon, Porto

2024-04-30

Recruiting

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

NCT05485961End Stage Kidney Disease

DrugClazakizumab

CSL Behring

Phase 2/3

3,110

Braga, Canelas-V.N.Gaia, Carregado, Faro, Lisbon, Loures, Oeiras, Porto

2024-04-27

Active, closed

A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

NCT06298552Generalized Myasthenia Gravis, gMG, Myasthenia Gravis, Generalized, Myasthenia Gravis

DrugEfgartigimod

argenx

Phase 3

119

Lisbon, Porto

2024-04-16

Recruiting

Management of Malignant Gastric Outlet Obstruction Between Surgery and Endoscopy

NCT06071507Gastric Outlet Obstruction, Pancreatic Cancer

IRCCS San Raffaele

Observational

250

Porto

2024-04-15

Recruiting

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

NCT06312176Breast Neoplasms

DrugsLiposomal doxorubicin·Abraxane·Xeloda·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

1,200

Lisbon, Porto

2024-04-14

Recruiting

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

NCT06330064Recurrent or Metastatic Solid Tumors

DrugIfinatamab Deruxtecan

Daiichi Sankyo

Phase 1/2

680

Lisbon, Porto

2024-04-10

Recruiting

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

NCT06312137Non Small Cell Lung Cancer

DrugsSacituzumab tirumotecan·Pemetrexed·Gemcitabine·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

780

Lisbon, Matosinhos Municipality, Coimbra, Porto

2024-04-03

Recruiting

EMOTE: a Smartphone Application for Binge Eating Based on DBT Skills

NCT06683456Binge Eating

Universidade do Porto

Not applicable

Porto

2024-04-01

Active, closed

Home-Based Exercise Program During Neoadjuvant Treatment to Improve Fatigue and Quality of Life in Early HER2-Positive and Triple-Negative Breast Cancer Patients

NCT06782698Triple Negative Breast Cancer (TNBC), HER2-Positive Breast Cancer, Early Breast Cancer, Cancer-related Fatigue

Centro Hospitalar Universitário de Santo António

Not applicable

Porto

2024-04-01

Recruiting

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

NCT06256588Neoplasms, Head and Neck

DrugDostarlimab

GlaxoSmithKline

Phase 3

864

Coimbra, Faro, Lisbon, Matosinhos Municipality, Porto, Vila Nova de Gaia

2024-03-21

Recruiting

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

NCT05835310Systemic Lupus Erythematosus

DrugAnifrolumab

AstraZeneca

Phase 3

100

Lisbon, Porto

2024-03-14

Recruiting

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

NCT05509777Crohn's Disease

DrugMirikizumab

Eli Lilly and Company

Phase 3

Braga, Lisbon, Porto

2024-03-13

Recruiting

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

NCT05923073Crohn's Disease

DrugsTremfya·Guselkumab

Janssen Research & Development, LLC

Phase 3

120

Braga, Lisbon, Porto

2024-03-13

Active, closed

Natriuresis With Acetazolamide or SGLT2 Inhibitors Added to Intravenous Loop Diuretics in Decompensated Heart Failure

NCT07926958Heart Failure, Acute Decompensated Heart Failure (ADHF)

DrugsAcetazolamide·Furosemide·Dapagliflozin

Universidade do Porto

Phase 4

Porto

2024-03-11

Active, closed

Does the Structure of the Tendon Relate to the Temporal, Kinetic and Kinematic Jump Variables? Athletes Vs. Non Athletes

NCT06732986Vertical Jump, Patellar Tendon, Achilles Tendon

Escola Superior de Tecnologia da Saúde do Porto

Observational

Porto

2024-03-05

Recruiting

Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)

NCT06165341Alpha1-Antitrypsin Deficiency

DrugFazirsiran

Takeda

Phase 3

Braga, Funchal, Porto

2024-03-01

Active, closed

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

NCT05827081Early Breast Cancer

DrugsLeuprolide·Goserelin·Exemestane·Ribociclib

Novartis Pharmaceuticals

Phase 3

1,466

Coimbra, Lisbon, Porto

2024-02-28

Recruiting

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT06161025Solid Cancer

DrugsR-DXd·Topotecan·Paclitaxel

Daiichi Sankyo

Phase 2/3

860

Amadora, Lisbon, Porto

2024-02-27

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy

NCT05979311HIV, HIV Infections

DrugsBictegravir·Dolutegravir·Emtricitabine·Lamivudine

ViiV Healthcare

Phase 3

463

Aveiro, Porto

2024-02-21

Active, closed

Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer

DrugTarlatamab

Amgen

Phase 3

404

Braga, Lisbon, Porto

2024-02-20

Active, closed

The Research Aims to Study the Effectiveness of a Physical Exercise Program on Indicators of Quality of Life and Functionality: It Will be Applied at Home to People Undergoing Cardiac Surgery, in Phase II of Cardiac Rehabilitation

NCT07153874Cardiac Surgery, Rehabilitation Program, Quality of Life, Functional Status

Universidade Católica Portuguesa

Not applicable

Porto

2024-02-19

Active, closed

ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function

NCT05907096Delayed Graft Function

DrugEmpasiprubart

argenx

Phase 2

103

Carnaxide, Lisbon, Porto

2024-02-17

Active, closed

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

NCT06151574Lung Cancer, Non-squamous, Non-small Cell

DrugsZongertinib·Pemetrexed·Keytruda·Cisplatin

Boehringer Ingelheim

Phase 3

428

Lisbon, Porto

2024-02-09

Active, closed

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

NCT06191744Follicular Lymphoma (FL)

DrugsEpcoritamab·Bendamustine·Obinutuzumab·Vincristine

Genmab

Phase 3

1,095

Lisbon, Vila Nova de Gaia, Porto

2024-02-05

Active, closed

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis

NCT06260163Colitis, Ulcerative

DrugsTremfya·Guselkumab

Janssen Research & Development, LLC

Phase 3

112

Lisbon, Porto

2024-01-19

Active, closed

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

NCT06079879Essential Thrombocythemia

DrugsAnagrelide·Bomedemstat·Busulfan·Ruxolitinib

Merck Sharp & Dohme LLC

Phase 3

340

Braga, Lisbon, Porto

2023-12-31

Recruiting

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

NCT05950945Breast Cancer

DrugTrastuzumab deruxtecan

Daiichi Sankyo

Phase 3

250

Braga, Lisbon, Porto

2023-12-30

Recruiting

Pegtibatinase as a Treatment for Participants With Classical Homocystinuria (HCU) Receiving Standard of Care Treatment

NCT06247085Homocystinuria

DrugPegtibatinase

Travere Therapeutics, Inc.

Phase 3

Coimbra, Lisbon, Porto

2023-12-28

Recruiting

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

NCT06119581Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

DrugsOlomorasib·Pemetrexed·Cisplatin·Carboplatin

Eli Lilly and Company

Phase 3

1,264

Coimbra, Lisbon, Porto

2023-12-21

Active, closed

A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo

NCT06118411Vitiligo

DrugUpadacitinib

AbbVie

Phase 3

614

Coimbra, Leiria, Lisbon, Porto

2023-12-19

Recruiting

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

NCT06136650Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms

DrugsFludrocortisone acetate·Opevesostat·Prednisone Acetate·Zytiga

Merck Sharp & Dohme LLC

Phase 3

1,314

Alcabideche, Vila Nova de Gaia, Braga, Lisbon, Porto

2023-12-18

Not yet open

Hydrophobic Tubes for the Treament of Lower and Upper Limb Lymphedema

NCT05970068Lymphedema of Leg

Universidade do Porto

Not applicable

Porto

2023-12-15

Recruiting

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

NCT06128629Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

DrugNexiguran ziclumeran

Intellia Therapeutics

Phase 3

1,200

Lisbon, Porto

2023-12-13

Recruiting

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

NCT06136559Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsNemtabrutinib·Ibrutinib·Acalabrutinib

Merck Sharp & Dohme LLC

Phase 3

1,200

Lisbon, Vila Nova de Gaia, Porto

2023-12-13

Recruiting

Validation of the C-mo System - Cough Monitoring

NCT05989698Cough, Asthma, Chronic Obstructive Pulmonary Disease, Gastro Esophageal Reflux

Cough Monitoring Medical Solutions

Not applicable

300

Alfena, Amadora, Aveiro, Coimbra, Lisbon, Porto

2023-12-11

Active, closed

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

NCT06065748Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

DrugsGiredestrant·Ribociclib·Abemaciclib·Palbociclib

Hoffmann-La Roche

Phase 3

1,050

Coimbra, Lisbon, Porto, Vila Nova de Gaia

2023-12-11

Active, closed

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

NCT06077760Non-small Cell Lung Cancer

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

868

Lisbon, Porto

2023-12-06

Recruiting

The Epithelioid Hemangioendothelioma Registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN)

NCT06408441Epithelioid Hemangioendothelioma, Sarcoma,Soft Tissue

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Observational

100

Porto

2023-12-01

Recruiting

Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study

NCT05809986Relapsing Multiple Sclerosis

Novartis Pharmaceuticals

Observational

174

Amadora, Guimarães, Leiria, Lisbon, Matosinhos Municipality, Ponte de Lima, Porto, Setúbal

2023-11-27

Active, closed

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

NCT06016738Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer

DrugsPalazestrant·Exemestane·Anastrozole·Letrozole

Olema Pharmaceuticals, Inc.

Phase 3

510

Coimbra, Lisbon, Porto, Senhora da Hora

2023-11-16

Recruiting

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

NCT05920356Non-Small Cell Lung Cancer (NSCLC)

DrugsLumakras·Sotorasib·Pembrolizumab

Amgen

Phase 3

750

Lisbon, Matosinhos Municipality, Porto

2023-11-16

Active, closed

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

NCT06062420Neoplasms, Head and Neck

DrugsRemzistotug·Nelistotug·Belrestotug·Dostarlimab

GlaxoSmithKline

Phase 2

316

Almada, Lisbon, Porto

2023-11-14

Active, closed

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

NCT05870579Breast Cancer

DrugsGa-NeoB·Lu-NeoB·Ribociclib·Fulvestrant

Novartis Pharmaceuticals

Phase 1

Porto

2023-11-13

Active, closed

A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

NCT06054555Melanoma

DrugsOpdivo·Nivolumab

Amgen

Phase 3

633

Setúbal, Lisbon, Porto

2023-11-02

Recruiting

Developing Trustworthy Artificial Intelligence (AI)-Driven Tools to Predict Vascular Disease Risk and Progression

NCT06206369Aneurysm Abdominal, Peripheral Arterial Disease

Amsterdam UMC, location VUmc

Observational

11,000

Porto

2023-10-31

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

NCT06025578Progressive Pulmonary Fibrosis

DrugAdmilparant

Bristol-Myers Squibb

Phase 3

1,057

Braga, Lisbon, Loures, Porto, Vila Nova de Gaia

2023-10-25

Recruiting

DESTINY Breast Respond HER2-(Ultra)Low Europe

NCT05945732Unresectable Breast Cancer, Metastatic Breast Cancer, HER2-low Expressing Breast Cancer, HER2-(Ultra)Low Expressing Breast Cancer

DrugTrastuzumab deruxtecan

Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Observational

2,295

Alcabideche, Lisboa, Amadora, Lisboa, Braga, Lisbon, Loures, Porto, Vila Real

2023-10-24

Recruiting

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

NCT05882058Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma

DrugObrixtamig

Boehringer Ingelheim

Phase 2

204

Lisbon, Porto

2023-10-13

Recruiting

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

NCT06012240Alopecia Areata

DrugUpadacitinib

AbbVie

Phase 3

1,500

Almada, Lisbon, Porto

2023-10-11

Active, closed

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

NCT05952557Breast Cancer, Early Breast Cancer

DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole

AstraZeneca

Phase 3

5,511

Amadora, Braga, Lisbon, Porto, Vila Nova de Gaia, Vila Real

2023-10-05

Active, closed

A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies

NCT05957367GIST

DrugRipretinib

Deciphera Pharmaceuticals, LLC

Phase 1/2

Porto

2023-09-28

Active, closed

Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

NCT06088290Leiomyosarcoma

DrugsLurbinectedin·Doxorubicin

PharmaMar

Phase 3

469

Lisbon, Coimbra, Porto

2023-09-21

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

NCT06003426Idiopathic Pulmonary Fibrosis

DrugAdmilparant

Bristol-Myers Squibb

Phase 3

1,255

Faro, Lisbon, Loures, Porto, Vila Nova de Gaia

2023-09-14

By invitation

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy

NCT05979441Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis, Polymyositis

DrugEfgartigimod PH20

argenx

Phase 3

240

Porto

2023-09-12

Recruiting

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

NCT06051617Primary Biliary Cholangitis

DrugSeladelpar

Gilead Sciences

Phase 3

402

Braga, Creixomil, Lisbon, Porto

2023-09-07

Active, closed

Exercise As Intervention in Chronic Lymphocytic Leukemia

NCT06396611Chronic Lymphocytic Leukemia

Universidade do Porto

Not applicable

Porto

2023-09-01

Recruiting

OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis

NCT06355934ATTR Amyloidosis

AstraZeneca

Observational

52,121

Lisbon, Porto

2023-08-21

Recruiting

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

NCT05947851Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma, Lymphoma, Small Lymphocytic

DrugsNemtabrutinib·Venetoclax·Rituximab

Merck Sharp & Dohme LLC

Phase 3

735

Porto

2023-08-08

Active, closed

Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)

NCT05797740Multiple Sclerosis

DrugsMavenclad·Cladribine

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Observational

366

Coimbra, Lisbon, Porto

2023-08-03

Active, closed

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

NCT05843643Systemic Lupus Erythematosus

DrugUpadacitinib

AbbVie

Phase 3

1,014

Guilhufe, Almada, Ponte de Lima, Porto

2023-07-25

Active, closed

A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

NCT05933577Melanoma

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

1,089

Lisbon, Porto

2023-07-19

Active, closed

A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight

NCT05726227Obesity

DrugSemaglutide

Novo Nordisk A/S

Phase 3

212

Lisbon, Porto

2023-07-07

Active, closed

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

NCT05827016Multiple Myeloma

DrugsIberdomide·Lenalidomide

Bristol-Myers Squibb

Phase 3

1,230

Braga, Coimbra, Porto

2023-06-22

Recruiting

The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)

NCT05427370Coronary Artery Disease, Heart Failure Systolic

Sunnybrook Health Sciences Centre

Not applicable

754

Lisbon, Porto

2023-06-22

Active, closed

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

NCT05889182Hidradenitis Suppurativa

DrugUpadacitinib

AbbVie

Phase 3

1,328

Lisbon, Porto

2023-06-21

Recruiting

Ganciclovir Resistant/Refractory Cytomegalovirus Infection in SOT Recipients and HSCT Patients

NCT05234723Cytomegalovirus Infections

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Observational

100

Porto

2023-06-19

Recruiting

A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

NCT05897320Episodic Migraine

DrugEptinezumab

H. Lundbeck A/S

Phase 3

315

Braga, Coimbra, Lisbon, Porto

2023-06-08

Active, closed

Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism

NCT05778071Chronic Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases

Alexion Pharmaceuticals, Inc.

Phase 3

165

Lisbon, Porto

2023-06-07

Recruiting

Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

NCT05714085Heart Failure, Left Ventricular Systolic Dysfunction

DrugVericiguat

Merck Sharp & Dohme LLC

Phase 2/3

342

Lisbon, Porto

2023-05-31

Active, closed

Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

NCT05740566Small Cell Lung Cancer (SCLC)

DrugsAmrubicin·Lurbinectedin·Tarlatamab·Topotecan

Amgen

Phase 3

509

Lisbon, Matosinhos Municipality, Porto

2023-05-31

Recruiting

A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma

NCT05562466Asthma

DrugBudesonide

Novartis Pharmaceuticals

Phase 3

200

Lisbon, Porto

2023-05-11

Recruiting

A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

NCT05716100Focal Onset Seizures

DrugAzetukalner

Xenon Pharmaceuticals Inc.

Phase 3

360

Coimbra, Guimarães, Lisbon, Porto, Santa Maria da Feira, Vila Real

2023-05-09

Recruiting

The Ailliance Post-Market Clinical Study

NCT05856370Spinal Deformity, Spinal Degenerative Disorder, Spinal Fusion Failure, Spinal Trauma

Medtronic Spinal and Biologics

Not applicable

1,000

Porto

2023-05-01

By invitation

An Open-label Study of XEN1101 in Epilepsy

NCT05718817Focal Epilepsy, Tonic-Clonic Seizures

DrugAzetukalner

Xenon Pharmaceuticals Inc.

Phase 3

880

Coimbra, Guimarães, Lisbon, Porto, Santa Maria da Feira

2023-04-25

Recruiting

Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women

NCT04124120Heart Diseases, Coronary Artery Disease, Coronary Artery Bypass Grafting

Weill Medical College of Cornell University

Not applicable

2,300

Coimbra, Lisbon, Porto

2023-04-17

Recruiting

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

NCT05774951Breast Cancer, Early Breast Cancer

DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole

AstraZeneca

Phase 3

4,300

Amadora, Braga, Guimarães, Lisbon, Matosinhos Municipality, Porto, Vila Nova de Gaia

2023-03-31

Active, closed

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

NCT05572515Multiple Myeloma

DrugsTeclistamab·Carfilzomib·Pomalidomide·Bortezomib

Janssen Research & Development, LLC

Phase 3

614

Almada, Braga, Lisbon, Porto, Vila Nova de Gaia

2023-03-29

Recruiting

Assessment of the Role of Incisura Biopsy in the Staging of Chronic Gastritis

NCT05744596Chronic; Gastritis, Atrophic

Clinical Hospital Colentina

Observational

400

Porto

2023-03-23

Active, closed

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease

DrugInclisiran

Novartis Pharmaceuticals

Phase 3

14,012

Almada, Carnaxide, Coimbra, Lisbon, Matosinhos Municipality, Porto, Santa Maria da Feira, Setúbal

2023-03-09

Recruiting

Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

NCT05677971Alpha1-Antitrypsin Deficiency

DrugFazirsiran

Takeda

Phase 3

160

Braga, Funchal, Porto

2023-03-06

Active, closed

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

NCT05702034Ischemic Stroke; Ischemic Attack, Transient

DrugMilvexian

Janssen Research & Development, LLC

Phase 3

12,523

Braga, Coimbra, Covilha, Guimarães, Lisbon, Porto, Pragal, Santa Maria da Feira

2023-02-15

Recruiting

A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

NCT05667142Primary Generalized Tonic-Clonic Seizures

DrugAzetukalner

Xenon Pharmaceuticals Inc.

Phase 3

160

Coimbra, Guimarães, Lisbon, Matosinhos Municipality, Porto, Santa Maria da Feira

2023-02-14

Active, closed

A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A

NCT05685238Haemophilia A, Haemophilia A With Inhibitors

Novo Nordisk A/S

Phase 3

451

Coimbra, Lisbon, Porto

2023-02-13

Active, closed

Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma

NCT05605899High-risk Large B-cell Lymphoma (LBCL)

DrugsAxi-cel·Axicabtagene Ciloleucel·Vincristine·Doxorubicin

Kite, A Gilead Company

Phase 3

300

Lisbon, Porto

2023-02-10

Active, closed

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

NCT05578976Diffuse Large B-Cell Lymphoma

DrugsEpcoritamab·Vincristine·Doxorubicin·Prednisone

Genmab

Phase 3

900

Braga, Lisbon, Porto

2023-02-08

Active, closed

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

NCT05555732Metastatic Non Small Cell Lung Cancer

DrugsDato-DXd·Pemetrexed·Keytruda·Cisplatin

Daiichi Sankyo

Phase 3

1,233

Lisbon, Porto

2023-01-11

Recruiting

NEgative prEssure Wound Therapy in Renal Transplant

NCT07065734Transplant Complication, Renal Transplant, Wound Complication

Centro Hospitalar De São João, E.P.E.

Phase 4

150

Porto

2023-01-01

Recruiting

European Myeloma Network (EMN) Sample Project

NCT06237803Multiple Myeloma, Smoldering Multiple Myeloma, Plasma Cell Leukemia, Extramedullary Myeloma

European Myeloma Network B.V.

Observational

6,000

Coimbra, Lisbon, Porto

2022-12-21

Active, closed

CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

NCT05681351Severe Hypertriglyceridemia

DrugOlezarsen

Ionis Pharmaceuticals, Inc.

Phase 3

885

Aveiro, Lisbon, Porto, Santa Maria da Feira

2022-12-13

Active, closed

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

NCT05445843Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation

DrugOpnurasib

Novartis Pharmaceuticals

Phase 2

Porto

2022-12-06

By invitation

An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

NCT05667493Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

DrugEplontersen

Ionis Pharmaceuticals, Inc.

Phase 3

1,400

Guimarães, Lisbon, Porto

2022-11-30

Recruiting

Pharmacokinetics and Safety of Rupatadine in Participants With Renal Impairment Compared to Control Participants

NCT06708520Renal Impairment

DrugRupatadine

Noucor Health S.A.

Phase 1

Gaia, Matosinhos Municipality, Porto

2022-11-21

Active, closed

Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

NCT05556096Generalized Myasthenia Gravis

Alexion Pharmaceuticals, Inc.

Phase 3

260

Almada, Porto

2022-11-21

Active, closed

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

NCT05444257Cystic Fibrosis

DrugVNZ/TEZ/D-IVA

Vertex Pharmaceuticals Incorporated

Phase 3

822

Lisbon, Porto

2022-11-08

Recruiting

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

NCT05457283Chronic Kidney Disease, Proteinuria, Children

DrugFinerenone

Bayer

Phase 3

100

Braga, Coimbra, Porto

2022-11-08

Active, closed

Xeltis Hemodialysis Access Graft: aXess Pivotal Study

NCT05473299End-stage Renal Disease

Xeltis

Not applicable

120

Lisbon, Porto, Sacavém

2022-11-04

Recruiting

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

NCT05552222Multiple Myeloma

DrugsTalquetamab·Teclistamab·Daratumumab·Lenalidomide

Janssen Research & Development, LLC

Phase 3

1,590

Braga, Lisbon, Porto

2022-10-25

Recruiting

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

NCT05253651Colorectal Neoplasms

DrugsTucatinib·Herceptin·Erbitux·Avastin

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

400

Almada, Guarda, Lisbon, Porto

2022-10-24

Active, closed

Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency

NCT05345171OTC Deficiency

DrugPrednisolone

Ultragenyx Pharmaceutical Inc

Phase 3

Porto

2022-10-18

Active, closed

A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer

NCT05587296Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer, Hot Flashes

Bayer

Phase 3

474

Loures, Braga, Coimbra, Lisbon, Porto

2022-10-14

Active, closed

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

NCT05565378Lung Cancer, Non-Small Cell

DrugsNelistotug·Belrestotug·Dostarlimab·Pembrolizumab

GlaxoSmithKline

Phase 2

351

Guimarães, Lisbon, Porto, Vila Nova de Gaia

2022-10-14

Recruiting

Met Non Small Cell Cancer Registry (MOMENT)

NCT05376891Cancer

EMD Serono Research & Development Institute, Inc.

Observational

700

Loures, Lisbon, Porto, Porto Covo

2022-10-04

Active, closed

A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease

NCT05347095Fistulizing Crohns Disease, Perianal Crohns Disease

DrugGuselkumab

Janssen-Cilag Ltd.

Phase 3

288

Braga, Lisbon, Porto

2022-09-27

Recruiting

Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT05327114Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

DrugNipocalimab

Janssen Research & Development, LLC

Phase 2/3

201

Almada, Braga, Porto

2022-09-23

Recruiting

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT05519085Relapsed or Refractory Multiple Myeloma

DrugsMezigdomide·Velcade·Pomalidomide·Bortezomib

Celgene

Phase 3

810

Braga, Lisbon, Porto

2022-09-20

Active, closed

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

NCT05531565Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus

DrugLitifilimab

Biogen

Phase 2/3

450

Coimbra, Lisbon, Porto, Viana do Castelo

2022-09-13

Recruiting

Asciminib Roll-over Study

NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

DrugsAsciminib single agent·Bosutinib·ABL001·Nilotinib

Novartis Pharmaceuticals

Phase 4

347

Lisbon, Porto

2022-08-30

Active, closed

Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials

NCT05492578Dermatitis Atopic

DrugAmlitelimab

Sanofi

Phase 2/3

1,856

Lisbon, Porto

2022-08-22

Active, closed

An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice

NCT05494606Ulcerative Colitis

AbbVie

Observational

785

Funchal, Almada, Faro, Lisbon, Loures, Porto, Viseu

2022-08-15

Active, closed

A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow

NCT05330325SGA, Turner Syndrome, Noonan Syndrome, ISS

DrugsNorditropin·Somapacitan

Novo Nordisk A/S

Phase 3

412

Lisbon, Porto, Vila Nova de Gaia

2022-08-10

Active, closed

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

NCT05242471Crohn's Disease

DrugsJNJ-78934804·Golimumab·Guselkumab

Janssen Research & Development, LLC

Phase 2

703

Lisbon, Portimão, Porto, Santa Maria da Feira

2022-07-22

Active, closed

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma

DrugsNemtabrutinib·Zilovertamab vedotin

Merck Sharp & Dohme LLC

Phase 2

189

Lisbon, Braga, Porto

2022-07-21

Active, closed

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

NCT05296798Locally Advanced or Metastatic Breast Cancer

DrugsPhesgo·Giredestrant·Pertuzumab·Trastuzumab

Hoffmann-La Roche

Phase 3

922

Coimbra, Lisbon, Loures, Porto

2022-07-18

Active, closed

Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

NCT05263934Eosinophilic Granulomatosis With Polyangiitis

DrugsDepemokimab·Mepolizumab

GlaxoSmithKline

Phase 3

163

Lisbon, Porto

2022-07-14

Active, closed

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

NCT05338970Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion

DrugPatritumab deruxtecan

Daiichi Sankyo

Phase 3

586

Lisbon, Porto

2022-07-08

Active, closed

Roll-over Study to Allow Continued Access to Ribociclib

NCT05161195Metastatic Breast Cancer

DrugsGoserelin·Tamoxifen·Anastrozole·Ribociclib

Novartis Pharmaceuticals

Phase 4

134

Lisbon, Loures, Porto

2022-07-07

Recruiting

The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

NCT05203172Solid Tumors

DrugsVemurafenib·Encorafenib·Binimetinib·Zirabev

Pfizer

Phase 4

210

Lisbon, Porto

2022-07-05

Active, closed

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT04975997Multiple Myeloma

DrugsIberdomide·Bortezomib·Daratumumab·Dexamethasone

Celgene

Phase 3

939

Coimbra, Lisbon, Porto

2022-06-23

Recruiting

A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB

NCT05183646FSGS

DrugRepagermanium

Dimerix Bioscience Pty Ltd

Phase 3

286

Braga, Carnaxide, Lisbon, Loures, Porto, Setúbal, Vila Franca de Xira, Vila Nova de Gaia

2022-05-30

Active, closed

PASS of Paediatric Patients Initiating Selumetinib

NCT05388370Neurofibromatosis Type 1

AstraZeneca

Observational

124

Lisbon, Porto

2022-05-23

Recruiting

Effects of Exergaming to Reduce Sedentary Time in Inactive Patients With Heart Failure

NCT05641662Cardiovascular Diseases

Linkoeping University

Not applicable

750

Porto

2022-05-16

Active, closed

A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.

NCT05109728Glioblastoma

Drugs[177Lu]Lu-DOTA-TATE·[68Ga]Ga-DOTA-TATE·Lutathera

Novartis Pharmaceuticals

Phase 1

Porto

2022-05-10

Active, closed

Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer

NCT05296746Breast Cancer Stage II

DrugRibociclib

SOLTI Breast Cancer Research Group

Phase 2

1,100

Lisbon, Porto

2022-05-03

Active, closed

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

NCT05270044Melanoma

Pierre Fabre Medicament

Phase 3

815

Lisbon, Porto

2022-05-02

Active, closed

Alternative Healthcare Delivery Strategies to Prevent Weight Regain After Bariatric Surgery

NCT05946187Obesity Adult Onset, Eating Behavior

University of Minho

Not applicable

144

Porto

2022-05-01

Recruiting

Autism Spectrum Disorder: BAEPs Findings and Behavioral Responses to Sounds

NCT05520632Autism Spectrum Disorder

Instituto de Ciências Biomédicas Abel Salazar

Observational

120

Porto

2022-05-01

Recruiting

Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

NCT05219617Seizures, Lennox Gastaut Syndrome

SK Life Science, Inc.

Phase 3

252

Lisbon, Porto, Almada

2022-04-28

Recruiting

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

NCT05061550Non-small Cell Lung Cancer

DrugsAZD0171·Pemetrexed/Cisplatin·Pemetrexed/Carboplatin·Monalizumab

AstraZeneca

Phase 2

630

Lisbon, Porto

2022-04-14

Recruiting

To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

NCT05356741Locally Advanced or Metastatic HER2-Expressing Cancers

DrugsKeytruda·Pembrolizumab

Vir Biotechnology, Inc.

Phase 1/2

645

Porto

2022-04-13

Active, closed

A Study of Rusfertide in Adults With Polycythemia Vera (PV)

NCT05210790Polycythemia Vera

DrugRusfertide

Protagonist Therapeutics, Inc.

Phase 3

293

Almada, Braga, Lisbon, Porto

2022-04-11

By invitation

Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)

NCT05248659Immunoglobulin A Nephropathy

DrugSibeprenlimab

Otsuka Pharmaceutical Development & Commercialization, Inc.

Phase 2/3

600

Braga, Carnaxide, Porto

2022-04-05

Active, closed

Tissue Level vs Bone Level Implants for Plural Restorations : a Multicentre Randomised Controlled Trial

NCT05223387Dental Implants, Edentulous

Anthogyr

Not applicable

Porto

2022-03-30

Active, closed

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

NCT05196035Chronic Kidney Disease, Proteinuria

DrugFinerenone

Bayer

Phase 3

219

Coimbra, Porto

2022-03-28

Recruiting

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT04928846Non Small Cell Lung Cancer, c-MET

DrugsTelisotuzumab vedotin·Docetaxel

AbbVie

Phase 3

768

Lisbon, Porto

2022-03-25

Active, closed

Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)

NCT05224141Small Cell Lung Carcinoma

DrugsPembrolizumab/Vibostolimab·Platinol-AQ·Tecentriq·Paraplatin

Merck Sharp & Dohme LLC

Phase 3

460

Lisbon, Porto

2022-03-24

Recruiting

Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis

NCT04804553Active Juvenile Psoriatic Arthritis

DrugApremilast

Amgen

Phase 3

Lisbon, Ponte de Lima, Porto, Vila Nova de Gaia

2022-03-17

Active, closed

Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)

NCT05248646Immunoglobulin A Nephropathy

DrugSibeprenlimab

Otsuka Pharmaceutical Development & Commercialization, Inc.

Phase 3

530

Braga, Carnaxide, Lisbon, Porto

2022-03-15

Active, closed

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

NCT05100862Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma

DrugsRuxience·Truxima·Zanubrutinib·Obinutuzumab

BeOne Medicines

Phase 3

799

Braga, Porto, VILA NOVA de GAIA Porto

2022-03-10

Active, closed

A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.

NCT05064878CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure, Epileptic Spasm, Refractory Seizures

DrugFintepla

Zogenix, Inc.

Phase 3

Lisbon, Porto

2022-03-08

Active, closed

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

NCT05215340Metastatic Non Small Cell Lung Cancer

DrugsDato-DXd·Keytruda·Pembrolizumab

Daiichi Sankyo

Phase 3

740

Lisbon, Porto

2022-03-04

Active, closed

Setrusumab vs Placebo for Osteogenesis Imperfecta

NCT05125809Osteogenesis Imperfecta

DrugSetrusumab

Ultragenyx Pharmaceutical Inc

Phase 2/3

183

Lisbon, Porto

2022-02-21

Active, closed

A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

NCT05221840Non-Small Cell Lung Cancer

DrugsMonalizumab·Oleclumab·Durvalumab

AstraZeneca

Phase 3

1,051

Lisbon, Loures, Porto

2022-02-07

Active, closed

A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)

NCT05063162Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)

DrugRozanolixizumab

UCB Biopharma SRL

Phase 3

113

Coimbra, Porto

2022-02-02

Active, closed

A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

NCT05071300Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

DrugEplontersen

Ionis Pharmaceuticals, Inc.

Phase 3

151

Lisbon, Porto

2022-01-04

Active, closed

Post Marketing Clinical Follow Up of the BioProtect Balloon Implant System

NCT05354440Prostate Cancer

BioProtect

Observational

Porto

2022-01-01

Active, closed

Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.

NCT05038735Breast Cancer

DrugsAlpelisib·Fulvestrant

Novartis Pharmaceuticals

Phase 3

210

Coimbra, Lisbon, Porto

2021-12-17

Recruiting

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

NCT04892173Carcinoma, Squamous Cell

DrugsJNJ-90301900·Erbitux·Cetuximab

Johnson & Johnson Enterprise Innovation Inc.

Phase 3

500

Braga, Lisbon, Porto, Vila Nova de Gaia

2021-12-10

Active, closed

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

NCT05152147Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma

DrugsZanidatamab·Herceptin·Trastuzumab·Adrucil

Jazz Pharmaceuticals

Phase 3

920

Almada, Coimbra, Guimarães, Lisbon, Matosinhos Municipality, Porto

2021-12-02

Recruiting

A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

NCT05164172Migraine

DrugEptinezumab

H. Lundbeck A/S

Phase 3

600

Almada, Braga, Coimbra, Porto

2021-12-01

Active, closed

A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)

NCT05060016Relapsed/Refractory Small Cell Lung Cancer

DrugTarlatamab

Amgen

Phase 2

222

Lisbon, Porto

2021-12-01

Recruiting

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

NCT04910685Indolent Systemic Mastocytosis, Smoldering Systemic Mastocytosis

Blueprint Medicines Corporation

Phase 2/3

534

Lisbon, Porto, Senhora Da Hor

2021-11-30

Active, closed

A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT05160584Relapsed/Refractory Multiple Myeloma

Janssen Pharmaceutica N.V., Belgium

Observational

256

Chaves, Coimbra, Porto

2021-11-18

Active, closed

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

NCT04988295Carcinoma, Non-Small-Cell Lung

DrugsLazertinib·Amivantamab·Pemetrexed·Carboplatin

Janssen Research & Development, LLC

Phase 3

776

Lisbon, Loures, Porto

2021-11-17

Active, closed

A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

NCT04812925Primary Immune Thrombocytopenia

DrugEfgartigimod PH20

argenx

Phase 3

173

Lisbon, Porto, Vila Nova de Gaia

2021-11-17

Active, closed

Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT05089734Non-Small Cell Lung Cancer

DrugsSacituzumab Govitecan·Docetaxel

Gilead Sciences

Phase 3

603

Coimbra, Lisbon, Matosinhos Municipality, Porto

2021-11-17

Active, closed

Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

NCT04994717Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)

DrugBlinatumomab

Amgen

Phase 3

303

Coimbra, Lisbon, Porto

2021-11-02

Recruiting

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

NCT05099172Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation

Bayer

Phase 1/2

430

Lisbon, Porto

2021-10-25

Active, closed

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive

DrugsBosutinib·Asciminib·ABL001·Nilotinib

Novartis Pharmaceuticals

Phase 3

405

Porto, Vila Nova de Gaia

2021-10-06

Active, closed

A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson Disease

NCT04884815Wilson Disease

Ultragenyx Pharmaceutical Inc

Phase 1/2

Lisbon, Porto

2021-09-27

Active, closed

A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT05023980Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsRiabni·Ruxience·Truxima·Pirtobrutinib

Loxo Oncology, Inc.

Phase 3

282

Braga, Lisbon, Porto

2021-09-23

Recruiting

International Rare And Severe Psoriasis Expert Network

NCT04359394Pustular Psoriasis (PP)

University Hospital, Basel, Switzerland

Observational

180

Porto

2021-09-22

Active, closed

A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease

NCT04929210Arthritis, Psoriatic

DrugsTremfya·Guselkumab

Janssen Research & Development, LLC

Phase 4

411

Braga, Guarda, Lisbon, Ponte de Lima, Porto

2021-08-30

Active, closed

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

NCT04961996Early Breast Cancer

DrugGiredestrant

Hoffmann-La Roche

Phase 3

4,170

Lisbon, Vila Nova de Gaia, Guimarães, Loures, Porto, Vila Real

2021-08-27

Active, closed

A Beta-only IL-2 ImmunoTherapY Study

NCT05086692Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer

DrugsKeytruda·Pembrolizumab

Medicenna Therapeutics, Inc.

Phase 1/2

160

Lisbon, Porto

2021-08-27

Active, closed

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

NCT04849728NASH - Nonalcoholic Steatohepatitis

Inventiva Pharma

Phase 3

1,000

Braga, Guimarães, Lisbon, Porto, Senhora da Hora, Vila Real

2021-08-19

Active, closed

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

NCT04923893Multiple Myeloma

DrugsCilta-cel·Bortezomib·Lenalidomide·Fludarabine

Janssen Research & Development, LLC

Phase 3

743

Lisbon, Porto

2021-08-19

Recruiting

Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

NCT04844866Diffuse Large B-cell Lymphoma

Miltenyi Biomedicine GmbH

Phase 2

213

Porto

2021-08-18

Recruiting

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

NCT04924075Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor

DrugBelzutifan

Merck Sharp & Dohme LLC

Phase 2

355

Lisbon, Porto

2021-08-12

Active, closed

Pulmonary Embolism International THrOmbolysis Study-3

NCT04430569Pulmonary Embolism

DrugAlteplase

Assistance Publique - Hôpitaux de Paris

Phase 3

800

Almada, Lisbon, Matosinhos Municipality, Porto, Setúbal

2021-08-04

Recruiting

Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

NCT04886804Neoplasm Metastasis, Non-Small Cell Lung Cancer

DrugZongertinib

Boehringer Ingelheim

Phase 1

554

Porto

2021-07-02

Active, closed

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

NCT04964934ER-Positive HER2-Negative Breast Cancer

DrugsCamizestrant·Anastrozole·Ribociclib·Abemaciclib

AstraZeneca

Phase 3

315

Guimarães, Lisbon, Loures, Porto, Vila Nova de Gaia

2021-06-30

Recruiting

A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine

NCT04965675Chronic Migraine in Children

DrugEptinezumab

H. Lundbeck A/S

Phase 3

285

Almada, Coimbra, Porto

2021-06-30

Active, closed

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

NCT04793958Advanced Colorectal Cancer, Metastatic Colorectal Cancer

DrugsAdagrasib·MFOLFOX6·Erbitux·Folfox

Mirati Therapeutics Inc.

Phase 3

461

Braga, Lisbon, Porto

2021-06-24

Active, closed

A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer

NCT04739761Breast Cancer

DrugTrastuzumab deruxtecan

AstraZeneca

Phase 3

506

Lisbon, Porto

2021-06-22

Active, closed

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

NCT04895358Breast Neoplasms

DrugsLiposomal doxorubicin·Abraxane·Xeloda·Taxol

Merck Sharp & Dohme LLC

Phase 3

342

Lisbon, Matosinhos Municipality, Porto

2021-06-18

By invitation

ManAgement of pRiapiSm and Its Impact on Outcomes

NCT04932902Priapism

Policlinic Hospital "G. Rodolico"

Observational

200

Porto

2021-06-01

Recruiting

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

NCT04844606Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease

DrugMirikizumab

Eli Lilly and Company

Phase 3

150

Braga, Lisbon, Porto

2021-05-26

Active, closed

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

NCT04704934Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

DrugsRamucirumab·Trastuzumab deruxtecan·Paclitaxel

Daiichi Sankyo

Phase 3

490

Creixomil E Mariz, Porto, Vila Real

2021-05-21

Active, closed

Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

NCT04544293Autoimmune Pulmonary Alveolar Proteinosis

DrugMolgramostim

Savara Inc.

Phase 3

164

Lisbon, Porto

2021-05-19

Active, closed

An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib

NCT04764188NSCLC

DrugAlectinib

Hoffmann-La Roche

Observational

800

Porto, Vila Nova de Gaia

2021-05-10

Active, closed

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

NCT04873362Breast Cancer

DrugsTrastuzumab emtansine·Herceptin·Tecentriq·Trastuzumab

Hoffmann-La Roche

Phase 3

1,188

Lisbon, Loures, Porto

2021-05-04

Active, closed

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

NCT04700124Bladder Cancer

DrugsEnfortumab Vedotin·Platinol-AQ·Keytruda·Gemcitabine

Merck Sharp & Dohme LLC

Phase 3

808

Coimbra, Lisbon, Porto

2021-04-21

Active, closed

Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)

NCT04822181Non-alcoholic Steatohepatitis

DrugSemaglutide

Novo Nordisk A/S

Phase 3

1,205

Senhora Da Hora, Matosinhos, Almada, Aveiro, Braga, Guarda, Guimarães, Lisbon, Porto

2021-04-01

Active, closed

Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)

NCT04944979Primary Immunodeficiency Disease

DrugKedrion IVIG

Kedrion S.p.A.

Phase 3

Lisbon, Porto

2021-03-31

Active, closed

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

NCT04586010Relapsing Multiple Sclerosis

DrugsFenebrutinib·Teriflunomide

Hoffmann-La Roche

Phase 3

746

Braga, Coimbra, Lisbon, Porto, Santa Maria da Feira

2021-03-17

Active, closed

SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity

NCT04775082Obesity

DrugLiraglutide

Novo Nordisk A/S

Phase 3

Lisbon, Porto

2021-03-04

Recruiting

A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

NCT04710576Chronic Graft-versus-host-disease

DrugAxatilimab

Syndax Pharmaceuticals

Phase 2

296

Lisbon, Porto

2021-03-04

Active, closed

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

NCT04685135Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer

DrugsAdagrasib·Taxotere·Docetaxel

Mirati Therapeutics Inc.

Phase 3

453

Almada, Braga, Coimbra, Guimarães, Lisbon, Loures, Porto, Santa Maria da Feira

2021-02-23

Recruiting

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

NCT04502394Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma

DrugsNavtemadlin·Acalabrutinib

Kartos Therapeutics, Inc.

Phase 1/2

Braga, Lisbon, Porto, Vila Nova de Gaia

2021-02-23

Active, closed

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

NCT04711252ER-Positive HER2-Negative Breast Cancer

DrugsCamizestrant·Anastrozole·Palbociclib

AstraZeneca

Phase 3

1,371

Braga, Guimarães, Lisbon, Loures, Porto, Vila Nova de Gaia

2021-01-28

Active, closed

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

NCT04589845Solid Tumors

DrugsCamonsertib·Belvarafenib·Pralsetinib·Divarasib

Hoffmann-La Roche

Phase 2

920

Porto

2021-01-18

Recruiting

SUrveillance of PREMalignant Stomach - Individualized Endoscopic Follow-up

NCT04613570Atrophic Gastritis, Intestinal Metaplasia, Gastric Dysplasia, Gastric Cancer

Instituto Portugues de Oncologia, Francisco Gentil, Porto

Not applicable

912

Porto

2021-01-02

Active, closed

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

NCT04640623Urinary Bladder Neoplasms

DrugsTAR-200·Cetrelimab

Janssen Research & Development, LLC

Phase 2

220

Almada, Aveiro, Guimarães, Lisbon, Loures, Porto, Vila Nova de Gaia, Vila Real

2020-12-18

Active, closed

Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia

NCT04490915Congenital Adrenal Hyperplasia

DrugCrinecerfont

Neurocrine Biosciences

Phase 3

182

Porto

2020-12-16

Active, closed

AMEND-CRT: Mechanical Dyssynchrony as Selection Criterion for CRT

NCT04225520Left Ventricular Dyssynchrony, Heart Failure, Cardiomyopathy, Dilated, Cardiac Remodeling, Ventricular

Universitaire Ziekenhuizen KU Leuven

Not applicable

500

Porto

2020-12-10

Active, closed

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

NCT04624204Small Cell Lung Cancer

DrugsOlaparib·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

672

Lisbon, Porto

2020-12-08

Active, closed

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

NCT04658862Urinary Bladder Neoplasms

DrugsTAR-200·Cetrelimab·Gemcitabine·Cisplatin

Janssen Research & Development, LLC

Phase 3

518

Almada, Coimbra, Lisbon, Porto

2020-12-07

Active, closed

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

NCT04622319HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer

DrugsTrastuzumab emtansine·Trastuzumab deruxtecan

Daiichi Sankyo

Phase 3

1,600

Guimarães, Lisbon, Loures, Matosinhos Municipality, Porto, Vila Nova de Gaia

2020-12-04

Active, closed

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

NCT04548999Multiple Sclerosis

DrugsOcrelizumab·Methylprednisolone

Hoffmann-La Roche

Phase 3

769

Braga, Lisbon, Porto

2020-12-03

Active, closed

Assessment of the Axone Micro Quadripolar Lead for Enhanced Cardiac Resynchronization Therapy

NCT04463641Heart Failure, Cardiac Resynchronization Therapy

MicroPort CRM

Not applicable

Lisbon, Porto

2020-12-03

Recruiting

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

NCT04613596Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer

DrugsAdagrasib·Pembrolizumab

Mirati Therapeutics Inc.

Phase 2/3

626

Coimbra, Guimarães, Lisbon, Porto, Vila Nova de Gaia

2020-12-02

Recruiting

ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

NCT04561518Transthyretin-Mediated Amyloidosis, ATTR Amyloidosis

Alnylam Pharmaceuticals

Observational

1,500

Lisbon, Porto

2020-11-23

Active, closed

A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

NCT04557059Prostatic Neoplasms

DrugsLhrha·Apalutamide

Janssen Pharmaceutica N.V., Belgium

Phase 3

691

Lisbon, Porto, Santa Maria da Feira

2020-11-12

Recruiting

LANDMARK Trial: a Randomised Controlled Trial of Myval THV

NCT04275726Aortic Valve Stenosis

Meril Life Sciences Pvt. Ltd.

Not applicable

988

Carnaxide, Lisbon, Porto

2020-11-04

Active, closed

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

NCT04544449Multiple Sclerosis, Primary Progressive

DrugsFenebrutinib·Ocrelizumab

Hoffmann-La Roche

Phase 3

985

Braga, Lisbon, Porto

2020-10-26

By invitation

A Study Following Males With Haemophilia A on Prophylaxis With Esperoct®

NCT04574076Haemophilia A

DrugTuroctocog alfa pegol

Novo Nordisk A/S

Observational

Lisbon, Porto

2020-10-23

Active, closed

Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

NCT04464226Cancer

DrugDarolutamide

Bayer

Phase 3

774

Almada, Lisbon, Porto

2020-10-20

Active, closed

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

NCT04446117Metastatic Prostate Cancer, Prostate Adenocarcinoma

DrugsZytiga·Xtandi·Abiraterone·Abiraterone acetate

Exelixis

Phase 3

575

Braga, Guimarães, Lisbon, Loures, Porto, Vila Real

2020-10-19

Active, closed

A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

NCT04538664Carcinoma, Non-Small-Cell Lung

DrugsAmivantamab·Pemetrexed·Carboplatin

Janssen Research & Development, LLC

Phase 3

308

Lisbon, Porto, Vila Nova de Gaia

2020-10-13

Active, closed

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

NCT04546009Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

DrugsGiredestrant·Palbociclib·Letrozole

Hoffmann-La Roche

Phase 3

992

Coimbra, Lisbon, Porto

2020-10-09

Active, closed

A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)

NCT04529772Diffuse Large B-Cell Lymphoma

DrugsAcalabrutinib·Vincristine·Doxorubicin·Prednisone

Acerta Pharma BV

Phase 3

611

Braga, Lisbon, Matosinhos Municipality, Porto, Vila Nova de Gaia

2020-10-08

Active, closed

A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors

NCT04434092Paroxysmal Nocturnal Hemoglobinuria

DrugsCrovalimab·Eculizumab

Hoffmann-La Roche

Phase 3

210

Aveiro, Lisbon, Porto

2020-10-08

Active, closed

Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer

NCT04590963Squamous Cell Carcinoma of the Head and Neck

DrugsMonalizumab·Erbitux·Cetuximab

AstraZeneca

Phase 3

370

Coimbra, Porto, Vila Nova de Gaia

2020-10-02

Active, closed

A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT04487080Carcinoma, Non-Small-Cell Lung

DrugsLazertinib·Amivantamab·Osimertinib

Janssen Research & Development, LLC

Phase 3

1,074

Lisbon, Porto

2020-09-30

Active, closed

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors

NCT04432584Paroxysmal Nocturnal Hemoglobinuria

DrugsCrovalimab·Eculizumab

Hoffmann-La Roche

Phase 3

190

Aveiro, Porto

2020-09-30

Active, closed

An Observational Real-world Study Evaluating Severe Tricuspid Regurgitation Patients Treated With the Abbott TriClip™ Device (bRIGHT)

NCT04483089Tricuspid Valve Regurgitation

Abbott Medical Devices

Observational

511

Porto

2020-08-27

Active, closed

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib

NCT04421963Ovarian Cancer, Breast Cancer

DrugOlaparib

AstraZeneca

Phase 3

185

Lisbon, Porto

2020-08-04

Active, closed

Personalized Therapy Study - HFRS (TriageHF) Post Approval Study

NCT04489225Heart Failure

Medtronic

Observational

2,200

Guimarães, Lisbon, Porto, Santarém

2020-08-01

Active, closed

Personalized Therapy Study - Intrinsic Antitachycardia Pacing Post-Approval Study (iATP PAS)

NCT04496518Ventricular Tachycardia

Medtronic

Observational

2,200

Guimarães, Lisbon, Porto, Santarém

2020-08-01

Recruiting

A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

NCT04307576Leukemia, Acute Lymphoblastic

DrugsInotuzumab Ozogamicin·Imatinib·Blinatumomab

Mats Heyman

Phase 3

6,430

Coimbra, Lisbon, Porto

2020-07-13

Recruiting

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT04221542Prostate Cancer

DrugsXaluritamig·Abiraterone·Enzalutamide

Amgen

Phase 1

479

Lisbon, Porto

2020-03-04

Active, closed

A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

NCT04191499Breast Cancer

DrugsInavolisib·Palbociclib·Fulvestrant

Hoffmann-La Roche

Phase 2/3

325

Lisbon, Porto

2020-01-29

Active, closed

A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension

NCT04175600Hypertension, Pulmonary

DrugSelexipag

Actelion

Phase 3

138

Lisbon, Porto

2020-01-16

Recruiting

A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis

NCT03969329Secondary Hyperparathyroidism

DrugEtelcalcetide

Amgen

Phase 3

Porto

2019-12-20

Recruiting

Terumo Aortic Global Endovascular Registry

NCT04246463Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm, Surgery

Vascutek Ltd.

Observational

1,000

Lisbon, Porto

2019-12-17

Active, closed

HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

NCT04153149Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

DrugVutrisiran

Alnylam Pharmaceuticals

Phase 3

655

Coimbra, Faro, Guimarães, Lisbon, Porto

2019-11-26

Active, closed

Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors

NCT04082429Haemophilia A Without Inhibitors, Haemophilia B Without Inhibitors

DrugConcizumab

Novo Nordisk A/S

Phase 3

156

Porto

2019-11-13

Recruiting

Boston Scientific Registry of Deep Brain Stimulation for Treatment of Essential Tremor (ET)

NCT04032470Essential Tremor

Boston Scientific Corporation

Observational

500

Porto

2019-10-23

Active, closed

Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors

NCT04083781Haemophilia A With Inhibitors, Haemophilia B With Inhibitors

DrugConcizumab

Novo Nordisk A/S

Phase 3

134

Porto

2019-10-21

Active, closed

A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

NCT03958877Multiple Sclerosis, Relapsing-Remitting

DrugsPlegridy·Avonex

Biogen

Phase 3

152

Lisbon, Loures, Braga, Coimbra, Porto

2019-10-18

Recruiting

Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia

NCT04793919Acute Promyelocytic Leukemia

DrugsMylotarg·All-trans retinoic acid·Arsenic Trioxide·ATRA

Associazione Italiana Ematologia Oncologia Pediatrica

Phase 2

Coimbra, Lisbon, Porto

2019-10-09

Active, closed

A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT04033445Ulcerative Colitis

DrugGuselkumab

Janssen Research & Development, LLC

Phase 2/3

1,064

Coimbra, Porto, Santa Maria da Feira, Viseu

2019-09-26

By invitation

A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

NCT03683186PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension

United Therapeutics

Phase 3

1,000

Almada, Coimbra, Lisbon, Porto

2019-09-23

Active, closed

An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis

NCT03950232Ulcerative Colitis

DrugEtrasimod

Pfizer

Phase 3

896

Coimbra, Vila Nova de Gaia, Guimarães, Porto

2019-09-05

Recruiting

International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma

NCT04043494Lymphoblastic Lymphoma, Childhood

DrugsVindesine·Thioguanine·PEG-Asparaginase·Ifosfamide

University Hospital Muenster

Phase 3

683

Coimbra, Lisbon, Porto

2019-08-23

Active, closed

A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

NCT04002297Mantle Cell Lymphoma; Non-Hodgkin Lymphoma

DrugsBendamustine·Zanubrutinib·Rituximab

BeOne Medicines

Phase 3

510

Lisbon, Porto

2019-08-20

Active, closed

Observational Evaluation of Atopic Dermatitis in Pediatric Patients

NCT03687359Dermatitis Atopic

Sanofi

Observational

1,860

Braga, Lisbon, Porto

2019-08-15

Active, closed

A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

NCT04035005Multiple Sclerosis, Primary Progressive

DrugOcrelizumab

Hoffmann-La Roche

Phase 3

1,013

Loures, Almada, Braga, Porto, Torres Vedras

2019-08-12

Recruiting

Pan Tumor Rollover Study

NCT03899155Cancer

DrugsRucaparib·Sunitinib·Trametinib·Relatlimab

Bristol-Myers Squibb

Phase 2

1,500

Lisbon, Porto

2019-08-09

Active, closed

Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

NCT03997123Triple Negative Breast Neoplasms

DrugsCapivasertib·Paclitaxel

AstraZeneca

Phase 3

923

Lisbon, Porto

2019-06-25

Active, closed

Adjuvant Palbociclib in Elderly Patients With Breast Cancer

NCT03609047Breast Cancer Stage II, Breast Cancer Stage III

DrugsDoxorubicin/cyclophosphamide·Palbociclib·Paclitaxel

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2

366

Lisbon, Porto

2019-06-14

Active, closed

Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)

NCT03992417Dermatitis Atopic

DrugDupilumab

Sanofi

Observational

955

Coimbra, Lisbon, Porto, Vila Nova de Gaia

2019-06-11

Active, closed

A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants

NCT03253263Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity, Intraventricular Hemorrhage, Retinopathy of Prematurity (ROP)

OHB Neonatology Ltd.

Phase 2

295

Almada, Lisbon, Porto

2019-05-09

Active, closed

A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

NCT03811561Diabetes Mellitus, Type 2

DrugSemaglutide

Novo Nordisk A/S

Phase 3

1,500

Senhora Da Hora, Matosinhos, Almada, Aveiro, Coimbra, Guimarães, Lisbon, Porto, Setúbal

2019-05-08

Active, closed

Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.

NCT03869892Metastatic Colorectal Cancer

DrugsTrifluridine/Tipiracil·Capecitabine

Institut de Recherches Internationales Servier

Phase 3

856

Almada, Coimbra, Lisbon, Loures, Porto

2019-03-21

Active, closed

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

NCT03748641Castration-Resistant Prostatic Cancer

DrugsAbiraterone acetate·Niraparib·Prednisone

Janssen Research & Development, LLC

Phase 3

765

Coimbra, Lisbon, Porto

2019-01-25

Active, closed

9-ING-41 in Patients With Advanced Cancers

NCT03678883Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer

DrugsCCNU·Lomustine·Abraxane·Adriamycin

Actuate Therapeutics Inc.

Phase 2

350

Lisbon, Porto

2019-01-04

Active, closed

A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve

NCT03682536Myelodysplastic Syndromes

DrugsEpoetin Alfa·Luspatercept

Celgene

Phase 3

363

Beja, Braga, Lisbon, Porto, Setúbal

2019-01-02

Active, closed

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

NCT03650114Relapsing Multiple Sclerosis

Drugs13-valent pneumococcal conjugate vaccine·23-valent pneumococcal polysaccharide vaccine·Ofatumumab

Novartis Pharmaceuticals

Phase 3

1,882

Braga, Coimbra, Lisbon, Loures, Matosinhos Municipality, Porto, Santa Maria da Feira

2018-12-28

Active, closed

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

NCT03725059Breast Cancer

DrugsEpirubicin·Adriamycin·Cytoxan·Taxol

Merck Sharp & Dohme LLC

Phase 3

1,240

Lisboa, Lisbon, Porto

2018-12-27

Active, closed

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

NCT03711032High-risk Non-muscle Invasive Bladder Cancer

DrugsKeytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

1,397

Braga, Coimbra, Lisbon, Porto

2018-12-24

Active, closed

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

NCT03765918Head and Neck Neoplasms

DrugsPlatinol-AQ·Keytruda·Cisplatin·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

714

Braga, Lisbon, Porto

2018-12-17

Active, closed

A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).

NCT03653507Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

DrugsZolbetuximab·Capecitabine·Oxaliplatin

Astellas Pharma Global Development, Inc.

Phase 3

507

Braga, Coimbra, Guimarães, Lisbon, Porto, Santa Maria da Feira, Setúbal, Vila Real

2018-11-28

Recruiting

Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)

NCT04174157Spinal Muscular Atrophy (SMA)

DrugZolgensma

Novartis Pharmaceuticals

Observational

700

Coimbra, Lisbon, Porto

2018-09-25

Active, closed

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

NCT03398135Ulcerative Colitis (UC)

DrugsSkyrizi·Risankizumab

AbbVie

Phase 3

1,242

Guimarães, Portimão, Santa Maria DA Feira, Almada, Coimbra, Lisbon, Porto, Viseu

2018-08-28

Recruiting

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

NCT03486873Solid Tumors, Hematologic Malignancies

DrugsPembrolizumab/Favezelimab·) Berahyaluronidase alfa·Olaparib·Lenvatinib

Merck Sharp & Dohme LLC

Phase 3

3,500

Lisbon, Porto

2018-08-21

Active, closed

Observation of Clinical Routine Care for Heart Failure Patients Implanted With BIOTRONIK CRT Devices

NCT03366545Heart Failure

Biotronik SE & Co. KG

Observational

3,030

Carnaxide, Evora, Lisbon, Porto

2018-05-14

Active, closed

A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

NCT03530397Selected Advanced Solid Tumors

DrugsVolrustomig·Nab-paclitaxel·Pemetrexed·Paclitaxel

MedImmune LLC

Phase 1

400

Lisbon, Porto

2018-04-24

Active, closed

Pyruvate Kinase Deficiency Global Longitudinal Registry

NCT03481738Pyruvate Kinase Deficiency

Agios Pharmaceuticals, Inc.

Observational

500

Coimbra, Lisbon, Porto

2018-04-23

Active, closed

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

NCT03466411Crohn's Disease

DrugsGuselkumab 1·Guselkumab 2·Guselkumab 3·Ustekinumab

Janssen Research & Development, LLC

Phase 2/3

1,409

Braga, Coimbra, Guimarães, Portimão, Porto, Santa Maria da Feira

2018-04-13

Active, closed

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

NCT03105102Crohn's Disease

DrugsSkyrizi·Risankizumab

AbbVie

Phase 3

1,336

Guimarães, Portimão, Lisbon, Santa Maria DA Feira, Almada, Faro, Loures, Porto

2018-04-09

Active, closed

Development of Novel Clinical Endpoints in Intermediate AMD

NCT03349801Age Related Macular Degeneration (AMD)

Frank G. Holz

Observational

718

Coimbra, Porto

2018-03-26

Active, closed

A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations

NCT03390504Urothelial Cancer

DrugsVinflunine·Erdafitinib·Docetaxel·Pembrolizumab

Janssen Research & Development, LLC

Phase 3

629

Lisbon, Porto

2018-03-23

Active, closed

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

NCT03345823Crohn's Disease

DrugUpadacitinib

AbbVie

Phase 3

747

Guimarães, Lisbon, Almada, Ponte de Lima, Porto

2018-03-21

Active, closed

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

NCT03330847Metastatic Triple Negative Breast Cancer

DrugCeralasertib

AstraZeneca

Phase 2

273

Lisbon, Loures, Porto, Vila Nova de Gaia

2018-03-07

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Portuguese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 November 2026. https://priyalifescience.com/clinical-trials-portugal/city/porto

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Portugal and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 1,102 studies in total at the last sync on 11 Nov 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 539 of those studies with a site in Porto.

How many clinical trials are recruiting in Porto?

235 of the 539 studies on this page are recruiting new participants as of the 11 Nov 2026, 03:18 UTC sync. A further 33 have not yet opened recruitment, 255 are active but closed to new participants, and 16 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Porto), 539 studies
Phase	Studies	Recruiting	Share
Phase 3	302	117	56%
Not applicable	71	32	13.2%
Observational	67	37	12.4%
Phase 2	42	19	7.8%
Phase 2/3	23	13	4.3%
Phase 4	12	6	2.2%
Phase 1	11	5	2%
Phase 1/2	11	6	2%

Most active sponsors

Lead sponsors with the most studies (Porto)
Lead sponsor	Studies	Recruiting
Universidade do Porto	33	9
Janssen Research & Development, LLC	31	13
AbbVie	26	9
AstraZeneca	24	8
Hoffmann-La Roche	24	4
Merck Sharp & Dohme LLC	24	12
Novartis Pharmaceuticals	20	7
Amgen	13	6
Novo Nordisk A/S	13	2
Boehringer Ingelheim	12	8

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.